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Abstract 
 
 Our hereditary material, the DNA, is on a daily basis subjected to endogenous and 
exogenous agents that lead to DNA damage. Therefore it is essential for the genomic integrity 
that these damages are repaired efficiently. As a response to DNA damage, cells have 
developed various repair mechanisms and defects in these are associated with cancer, ageing, 
and various neurodegenerative diseases. Therefore it is important to understand how the DNA 
is repaired and how the genetic information is preserved. A broader understanding of the 
DNA repair enzymes and how they function is an important matter. 
 Endonuclease V (EndoV) is a highly conserved DNA repair enzyme found in most 
organisms from prokaryotes to human. Prokaryotic EndoV has affinity for deaminated bases 
in DNA. Escherichia coli EndoV recognizes and binds to deaminated adenine (hypoxanthine), 
and cleaves the DNA stand at the second phosphodiester bond 3’ of the lesion. The high 
degree of conservation in the EndoV family suggests an important function also in the 
eukaryotic cell. The aim of this thesis has been to characterize the endonuclease V homologs 
from Homo sapiens and Mus musculus. 
 The results from this study show that there are a high (and uncertain) number of 
isoforms of human ENDOV, which makes it difficult to characterize and determine the 
function of this protein. The full-length hENDOV transcript (exon 3-contaning) does not 
represent the majority of the transcript variants in human cells, which is unexpected since 
exon 3 is known to make up the core of the protein. In line with this, endogenous full-length 
hENDOV protein could not be detected, neither in Western analysis or by 
immunoprecipitation.  
 Intracellular localisation of hENDOV fused to EGFP showed that isoform 1 was 
located to the cytoplasm and nucleus with enrichment in nucleoli in transfected HeLa-S3 
cells, whereas the other two isoforms showed only localization in the cytoplasm. Cells 
expressing hENDOV isoform 1 was exposed to DNA damaging agents, and interestingly, 
after CPT exposure hENDOV was excluded from the nucleoli. The role of hENDOV in the 
nucleoli remains unclear.  
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 The viability assay (MTT-assay) on primary mouse embryonic fibroblast (MEF) cell 
lines with or without mEndoV revealed no difference in survival after treatment with DNA 
damaging agents.  
 In summary, this thesis presents the first the characterization of the human ENDOV 
protein. Despite high conservation in all domains of life and current results, the function of 
mammalian EndoV is still unclear and further studies are needed.  
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Sammendrag 
 
 Arvestoffet vårt, DNA, utsettes daglig for endogene og eksogene forbindelser som 
fører til ulike skader. Effektiv reparasjon av skadene er essensielt for å opprettholde genomets 
integritet. Cellene har utviklet ulike reparasjonsmekanismer, som involverer mange 
forskjellige enzymer, som respons på DNA skadene. Feil eller mangler i 
reparasjonsmekanismene er assosiert med kreft, aldring og ulike neurodegenererende 
sykdommer. En større forståelse av enzymene som deltar og hvordan de fungerer er viktig for 
å forstå hvordan DNA blir reparert og hvordan den genetiske informasjonen bevares. 
 Endonuklease V (EndoV) er et svært konservert gen fra prokaryoter til mennesker. 
Prokaryotisk EndoV har en substratspesifisitet for deaminated baser i DNA. Escherichia coli 
EndoV gjenkjenner og binder til deaminert adenin (hypoxantin) og kutter den andre 
fosfodiester binding på DNA tråden på 3’ side av skaden. Siden EndoV er godt konservert 
antas at dette proteinet har en viktig funksjon i eukaryotiske celler. Formålet med denne 
oppgaven har vært å karakterisere funksjonen til endonuklease V i fra Homo sapiens og Mus 
musculus 
 Resultatene fra denne studien viser at det er et høyt (og usikre) antall isoformer av 
human ENDOV, noe som gjør det vanskelig å karakterisere og bestemme funksjonen til dette 
proteinet. I humane celler kan det virke som at de fleste transkripter mangler ekson 3. Dette er 
overraskende, siden ekson 3 tilsvarer kjernen av proteinet. Det ble heller ikke detektert 
endogent hENDOV i celle lysat ved immunopresipitering.   
 Intracellulær lokalisering av hENDOV isoform 1 fusjonert med EGFP, ble lokalisert 
til cytoplasma og i nukleus med anrikning i nukleoli i transfekterte HeLa-S3 celler. De to 
andre isoformene viste kun lokalisering i cytoplasma. Etter eksponering med det DNA-
skadene stoffet CPT, ble hENDOV isoform 1 eksludert fra nucleoli, men rollen for hENDOV 
i nukleoli er fortsatt uklar. 
  MTT-assayene på cellelinjene av primære muse embryonale fibroblast (MEF) 
viste ingen forskjell i overlevelse etter behandling med DNA skadene agens mellom de 
cellelinjene hvor genet for mEndoV har blitt slått ut, mot de cellelinjene der genet fortsatt var 
intakt. 
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  Kort oppsummert, presenterer denne oppgaven er den første karakteriseringen av den 
humane ENDOV protein. Til tross for den høye graden av konserveringen i pattedyr, er 
funksjonen av mammalsk EndoV fortsatt uklart så videre studier er nødvendig. 
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1 Introduction 
 Deoxyribonucleic acid (DNA) is the carrier of the genetic information and contains 
the instructions for the development and functioning of living organisms. Maintenance of the 
genome is therefore crucial for life. A variety of both exogenous and endogenous reactive 
compounds present a constant threat to the integrity of the DNA in living cells. To cope with 
the frequent challenge of endogenous and exogenous DNA insult, all eukaryotic cells have 
evolved a versatile DNA damage response (Figure 1.1). When DNA damage is detected, cell 
cycle checkpoint are activated to arrest cell cycle progression so that the DNA can be repaired 
before being passed to daughter cells (Nyberg et al. 2002;Hakem 2008). In addition to 
checkpoint activation, transcriptional programs are induced and if the level of damage is 
severe, apoptosis is initiated. To ensure that the genetic material is properly maintained, 
duplicated, and segregated within the cell, all the above processes are carefully coordinated. 
Defects in the DNA damage response and DNA repair processes have been shown to be 
involved in genetically inherited disorders, in ageing, and in carcinogenesis, and these 
findings underscore the importance of intact DNA checkpoint regulation and DNA repair for 
proper function and survival of the organism (Hoeijmakers 2001;Thoms et al. 2007;Hakem 
2008;Altieri et al. 2008).  
 The sources of DNA damaging agents may be exogenous (sunlight, tobacco smoke 
and food constituents), or endogenous (water and reactive oxygen species (ROS)). They may 
induce different types of DNA damage, ranging from single base alterations to bulky helix-
distorting lesions and single- and double-strand DNA breaks (SSB/DSB)  (Barnes and 
Lindahl 2004). DNA repair is probably the most important cellular mechanism against these 
modifications and hence the development of cancer and neurodegenerative diseases. This is 
illustrated by rare syndromes like Cockayne’s syndrome (CS), the Xeroderma pigmentosum 
(XP) syndrome and Trichothiodystrophy (TTD) caused by defective DNA repair and whose 
patients are prone to cancer and neurodegeneration. To facilitate therapeutic methods in 
addition to preventative strategies for these diseases, the knowledge of how the human 
organism preserves genomic integrity is crucial. 
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Figure 1.1. The DNA damage response. DNA damage is caused by a variety of sources. The 
cellular response to damage may involve activation of a cell cycle checkpoint, initiation of 
transcriptional programs, and induction of DNA repair or apoptosis (adapted from: 
http://rndsystems.com/mini_review_detail_objectname_MR03_DNADamageResponse.aspx). 
 
1.1 DNA damage 
 Oxidative DNA damage 1.1.1
 All mammals use oxygen as a life giving source, but paradoxically this molecule can 
also inflict huge problems for the organism. Normal aerobic metabolism generates oxygen 
metabolites called ROS that can attack intracellular macromolecules such as lipids, proteins 
and nucleic acids. ROS is also a result exogenous compounds such as UV radiation, 
chemicals (such as herbicides, algaecides, fungicides, bactericides, and viricides), and 
cigarette smoke (Kow 1999;Maynard et al. 2009). Free radicals are defined as species 
component of independent existence that contains one or more unpaired valence shell 
electron. Other common ROS compounds: the highly reactive hydroxyl radical (OH •), 
superoxide anion (O2
-
 •) and the non-radical H2O2 (Burney et al. 1999;Maynard et al. 2009) . 
The cells can prevent the damage inflicted by free radicals with antioxidants, which are 
compounds that inactivate oxidants to less reactive compounds. As previously mentioned free 
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radicals can damage lipids, proteins and RNA, but these molecules can, unlike DNA, the cell 
can created new of if they are damaged (Kow 1999;Maynard et al. 2009). One prominent 
damage coused by ROS on DNA is 7,8-dihydro-8-oxoguanine (8-oxoG) (Slupphaug et al. 
2003). This base lesion can form a Hoogsteen base pair with adenine during replication, and 
will lead to a G:C to T:A transversion mutation if not repaired (Kirouac and Ling 2011). 
Other dominant damages to DNA are ring-opened formamidopyrimidines (faPy), 
hydroxycytosine, and thymine glycol (Slupphaug et al. 2003). 
 DNA deamination 1.1.2
 Hydrolytic deamination of DNA is the spontaneous removal of an amine group from a 
DNA base (Lindahl 1993). The amino group is then replaced by a keto group that give the 
bases other properties. The deamination can be greatly enhanced by ROS, ionizing radiation, 
and nitrous acid (HNO2) (Kow 2002). Cytosine, adenine, guanine, and 5-methylcytosine can 
be deaminated to form uracil, hypoxanthine, xanthine, and thymine, respectively (Shapiro and 
Shiuey 1969;Kow 2002). Deaminated cytosine, uracil, will produce G:U mismatches that 
results in G:C → A:T transition mutations following replication (Schouten and Weiss 
1999;Barnes and Lindahl 2004). U:G mismatches are recognized by E. coli Endonuclease V 
(EcEndoV) (Gates and Linn 1977). The deamination product, hypoxanthine, can also be 
repaired by two different enzymes, the alkylbase DNA glycosylase, AlkA, which initiates 
repair by removal of the damaged base and EndoV. EndoV initiates repair by hydrolyses the 
second phosphodiester bond 3’ to the lesion (Saparbaev and Laval 1994;Schouten and Weiss 
1999). The corresponding nucleoside hypoxanthine is called inosine. Lindahl and Nyberg 
showed in 1974 that the heat induction hydrolytic deamination of cytosine occurs to a much 
greater extent in single-stranded DNA than double-stranded DNA. This is due to the helix 
structure of double-stranded DNA that protects residues from being deaminated (Barnes and 
Lindahl 2004).  
 Alkylated damage DNA 1.1.3
 Alkylating agents are formed endogenously as well as being widely present in the 
environment in food, cigarette smoke, chemicals, and chemotherapeutic (Sedgwick 2004). An 
important alkylating agent is the cellular methyl donor S-adenosyl-methionine (SAM) 
(Barrows and Magee 1982;Rydberg and Lindahl 1982;Naslund et al. 1983). SAM participates 
in several mammalian methylation reactions, including the methylation of cytosine to from 5-
methylcytosine. Alkylating agents can transfer alkyl groups to the nucleophile bases in DNA 
by attacking the O-and N-positions in base, either through mono- or bifunctional attacks 
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(Brookes and Lawley 1964;Lindahl 1993;Drabløs et al. 2004). Monofunctional alkylating 
agents have one active group that forms the binding to nucleophilic centres in DNA, while 
bifunctional alkylating agents have two active groups that can react with two sites on DNA at 
once results in more complex damages (Drabløs et al. 2004). Among alkylating chemicals are 
chloroacetaldehyde (CAA) and methyl methanesulfonate (MMS) that cause base damage 
which may lead to, incorrect base pairing (mutagenic), or blocking of replication (cytotoxic) 
(Rannug et al. 1976;Lundin et al. 2005). 
 Depurination and depyrimidiation 1.1.4
 Depurination or depyrimidiation is a major DNA damage is the DNA, where a DNA 
base is lost and an apurinic/apyrimidinic site (AP-site) is created. AP-site can be formed 
spontaneously by hydrolysis or as intermediates of base excision repair. Bases are removed 
from DNA by DNA glycosylase cleavage of N-glycosidic bonds, while the sugar-phosphate 
chain is kept intact (Friedberg et al. 2006). Depurination occurs with a relatively high 
frequency. Lindahl and Karlström estimated in 1973 that 2,000 - 10,000 residue in each 
mammalian cell are depurinated in each generation, while depyrimidiation occurs at a lower 
rate (Lindahl and Karlstro 1973).  
 Endogenous DNA damage 1.1.5
 DNA in one human cell is estimated to be subject to approximately 20.000 lesions 
each day due to normal metabolism (Friedberg et al. 2006). The most common damage is the 
hydrolysis of DNA, with depurination as the most prevalent incident. Other frequent 
occurring endogenous lesions are generated by oxidation and non-enzymatic methylation of 
DNA bases (Lindahl and Barnes 2000). 
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1.2 DNA repair 
 The first to discover that exogenous compounds could lead to mutations was Hermann 
Muller in the late 1920s, initiating the research how the cells responded to the different 
damages (Friedberg 2003). In the years after it, several DNA repair pathways were identified 
showing high degree of conservation from microorganisms to human cells (Klungland 2001). 
These repair mechanisms include more than 150 different genes that are involved in different 
aspects of DNA repair (Wood et al. 2005). 
 Overview of DNA repair mechanisms 1.2.1
 The DNA repair can be divided into six major mechanisms: (i) DNA repair by direct 
reversal, (ii) base excision repair (BER), (iii) nucleotide excision repair (NER), (iv) nucleotide 
incision repair (NIR), (v) mismatch repair (MMR), and  (vi) double-strand breaks repair 
(DSBR). 
The importance of DNA repair is reflected in the severe diseases and syndromes that appear 
where there are defects in these repair mechanisms (Thoms et al. 2007). 
 Direct reversal 1.2.2
 Unlike other DNA damage repair pathways, direct reversal is a single-step process that 
does not include multiple proteins or excision of damaged DNA (Sedgwick et al. 
2007;Hakem 2008). Direct reversal restores the correct base without removing the damage 
base, thus no toxic or mutagenic intermediates are generated (Hansen and Kelley 2000). There 
are several direct repair enzymes reversing different kinds of DNA damage. DNA-photolyase 
reverses UV-induced thymine dimers by using photons from blue light energy source (Sancar 
1990;Todo 1999). Another example of direct reversal is mediated O
6
-methylguanine DNA 
methyltransferase (MGMT) which removes the methyl group of O
6
-metghylguanine (Hakem 
2008;Hoeijmakers 2009). MGMT performs this important task in a reaction that inactivates 
the repair enzyme (Mishina et al. 2006). The enzyme being sacrificed for the repair of one 
single damaged base, and is thus named a “suicide protein” (Liu et al. 2002;Sancar et al. 
2004). AlkB is a 2-oxoglutarate- and iron-dependent DNA repair enzyme that releases 
replication blocks in alkylated DNA by a mechanism involving oxidative demethylation 
(Falnes et al. 2002;Trewick et al. 2002;Aas et al. 2003). Eight AlkB homologs are identified 
in human cells (Kurowski et al. 2003): ALKBH2 and ALKBH3 are two human homologs of 
the E. coli AlkB protein, that have shown directly reverse of 1-methyladanine and 3-
metylcytosine damage in DNA (Aas et al. 2003;Ringvoll et al. 2006). 
  Introduction 
6 
 
 Base excision repair 1.2.3
 Base excision repair is the major repair pathway for handling endogenous DNA 
lesions. BER repairs the highest number of DNA lesions in the cells.  This can be lesions 
which, typically consisting of bases modified by relatively small chemical groups, that are 
induced by ROS, methylation, deamination and hydroxylation (Krokan et al. 2004;Dalhus et 
al. 2009). The BER pathway is highly conserved among organisms ranging from E. coli to 
human (Izumi et al. 2003;Fortini et al. 2003). The repair is initiated by damaging specific 
enzymes called DNA glycosylases, which recognise and removes the damaged base. DNA 
glycosylases catalyse the hydrolysis of the glycosylic bond between the base and the sugar of 
the deoxyribose-phosphate backbone. This leads to release of the damaged base and leaving 
an AP-site that is both cytotoxic and mutagenic, and requires further processing. The BER 
pathway may proceed by either “short-patch” (Figure 1.2A and B), involving single 
nucleotide repair gap, or “long-patch repair” (Figure 1.2C), involving two or more nucleotide 
repair gaps, after the damage base has been removed by DNA glycosylase and incision has 
been made by an AP endonuclease (Kubota et al. 1996;Klungland and Lindahl 1997). In the 
short-patch repair the DNA glycosylases only remove the damage base, the gap is filled by 
DNA polymerase β (Polβ) and DNA ligase III (Lig III) ligates the strand to complete the 
repair. X-ray repair cross complementing 1 protein (XRCC1) is essential for efficient repair of 
single strand break repair and stimulates the two last proteins in the pathway (Kubota et al. 
1996;Brem and Hall 2005). In long-patch repair the strand containing the 5’-deoxyribose 
phosphatase (dRP) at the incised AP-site is replaced by several nucleotides. The DNA 
polymerase β, δ and ε synthesize and insert a longer stretch of DNA (2-13 nucleotides) 
starting at the AP-site (Fortini et al. 1998;Stucki et al. 1998;Prasad et al. 2000). This creates a 
5`-flap that is removed by the flap endonuclease 1 (FEN1) (Klungland and Lindahl 1997). 
The repair is completed by a DNA ligase I (Lig I) which seals the nick. The BER pathway 
was discovered 36 years ago when it was found that deaminated cytosine (uracil) was released 
as a free base (Lindahl 1974). 
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Figure 1.2. The BER pathway is initiated by DNA glycosylases and may follow a short-patch (A and 
B) or a long-patch (C) route, in part depending on the type of initiating DNA glycosylase. The 
catalytic protein in each step is underlined (Nilsen and Krokan 2001). 
 
 Nucleotide excision repair 1.2.4
 Nucleotide excision repair (NER) is one of the most versatile repair mechanisms and 
can repair many different types of damages (Vermeulen et al. 1997). This pathway is 
responsible for removal of numerous bulky DNA adducts induced by agents such as UV light 
and chemicals (polycyclic aromatic hydrocarbons, aromatic amines, and N-nitroso 
compounds) (Balajee and Bohr 2000). Errors in this repair mechanism can cause serious 
diseases such as xeroderma pigmentosum, Cockayne's syndrome, and Trichothiodystrophy 
(Lehmann 2001;Mellon 2005). NER pathway can be divided into two sub pathways: global 
genome repair (GGR) and transcription coupled repair (TCR). GGR is active in the entire 
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genome and removes DNA lesions throughout the genome. It is responsible for the repair of 
the non-transcribed strand of expressed genes and for the repair of unexpressed regions of the 
genome. TCR ensures quick repair of actively transcribed genes and is specialized to remove 
damaged DNA from the transcribed strand of transcriptionally active genes (Mellon et al. 
1987;Christmann et al. 2003). NER removes a short stretch of DNA around the damaged 
region, 12-13 nucleotides in prokaryotic and 24-32 nucleotides in eukaryotic cells. The gap is 
then filled by DNA polymerases δ, ε or κ, using the complementary strand as template to 
resynthesize the excised nucleotide sequence, and finally the newly synthesized repair patch is 
ligated to the pre-existing strand (Vermeulen et al. 1997;Reardon and Sancar 2005;Ogi et al. 
2010). This repair pathway is conserved from prokaryotes to eukaryotes (Seeberg et al. 1976). 
 Nucleotide incision repair 1.2.5
 In 2002, the NIR pathway was first discovered by Ischenko and Saparbaev as a 
glycosylase-independent incision method of oxdatively damage DNA by E. coli endonuclease 
IV (Nfo) and the homologue Saccharomyces cerevisiae Apn1 enzymes (Ischenko and 
Saparbaev 2002). The NIR pathway is initiated when an AP endonucleases, incise DNA 5’ to 
a number of oxidatively damaged bases. The AP endonuclease leaves the lesion attached to 
the 5’ end of the downstream fragment and on OH-group on the 3’end of the nicked site. NIR 
has an advantage over BER: does not form AP sites, and thereby avoids the genotoxic 
intermediates like BER (Gros et al. 2004). Gros and co-workers reported that Ape1 is the 
major AP endonucleases in human cells, and there was specific endonuclease damage in the 
NIR Pathway (Gros et al. 2004). The NIR pathway is conserved from E. coli to humans 
(Ishchenko et al. 2003;Gros et al. 2004). Downstream steps in NIR pathway is poorly 
described and it is suggested that NIR merged with long-patch BER (Ischenko and Saparbaev 
2002).  
 DNA mismatch repair 1.2.6
 DNA mismatch repair (MMR) is a system for eliminating base-base mismatch and 
insertion/deletion loops, which have been introduced by replication misincorporation and 
slippage (Hoeijmakers 2001;Christmann et al. 2003). MMR repair strategy is an integrated 
part of DNA replication (Friedberg et al. 2006) and is highly conserved from E. coli to 
mammals (Li 2008). In bacteria, yeast and higher eukaryotes, different types of MMR exits, 
still the general MMR process have many similarities (Fishel and Kolodner 1995). The MMR 
repair machinery must distinguish between the “correct” and “mismatched” DNA strand in 
order not to introduce a mutation (Yang 2000;Christmann et al. 2003). Mutations in MMR 
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genes are associated with an increase in the frequency of spontaneous mutation a contributing 
factor to hereditary nonpolyposis colorectal cancer (HNPCC) (Leach et al. 1993;Fishel et al. 
1994). MMR is also involved in cell cycle arrest and apoptosis (Li 2008). 
 MMR is strand-specific, and as for most other DNA repair pathways is well 
characterized in E. coli. MutS initiates MMR by recognizing mismatches in DNA. Then MutL 
and MutH are recruited. This protein complex activates a methylation-specific endonuclease 
activity of MutH, which nicks the newly synthesized DNA strand at hemi-methylated GATC 
site near the mismatch (Nowosielska and Marinus 2008). DNA helicase II then separates the 
two strands and exonuclease excises the DNA from the nick past the mismatch (Dao and 
Modrich 1998). The DNA polymerase δ and coats ssDNA fills in the gap and DNA ligase 
seals the strand (Lahue et al. 1989;Kunkel and Erie 2005).  
 Eukaryotes have a similar mechanism for MMR, but are more complicated because of 
several MutS- and MutL- homologous proteins. The details of MMR in the eukaryotic 
pathway is not fully understood, but the damage excision and strands synthesis is carried out 
by Exonuclease I (ExoI), replication protein A (RPA), proliferating cellular nuclear antigen 
(PCNA), DNA polymerase δ, and DNA ligase I (Li 2008). 
 Double-strand breaks repair 1.2.7
  Recombination repair is fundamental cellular process in all living organisms; it is 
responsible for correction of double-strand breaks (DSBs). DSBs must be efficiently repaired 
to restore the integrity and functionality of the genome. If the cell does not repair this damage 
it can be lethal (Cahill et al. 2006). These DSBs may occur as a result of ROS, ionizing 
radiation, various chemicals or due to collapsed replication fork (Karran 2000). 
 The DSBs repair pathway can be divided into two main repair pathways, non-
homologous DNA end-joining (NHEJ) and homologous recombination (HR). Both 
mechanisms are evolutionarily conserved (Lee and McKinnon 2007). Depending on the 
position in the cell cycle, one of the two repair mechanisms is activated, or both pathways 
may be activated to simultaneously and cooperatively repair DNA lesion (Moore and Haber 
1996). NHEJ is most active in G0/G1, whereas HR occurs mostly in late S and G2 phase 
(Christmann et al. 2003). Although the two repair mechanisms are different and involve many 
different enzymes, both require kinase ATM to signal failure and locate the damage. One 
other area that is different is that NHEJ which leads to an increase or loss of a few 
nucleotides, while HR is an error-free repair mechanism (Slupphaug et al. 2003). 
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1.2.7.1 Homologous recombination  
 After a double strand breaks, a complex of exonucleases consisting of 
Mre11/Rad50/NBS1 (M/R/N) will remove additional nucleotides in 5’ → 3’ direction form 
one of the damage strands, causing single-strand ends, as shown in Figure 1.3A. Rad52 in 
eukaryotes and RecA in prokaryotes binds to the 3’ single-strand tails and ensure that RAD51, 
along with several proteins, will help to find the homologous sequence in the sister 
chromatids (Slupphaug et al. 2003). Initiating a strand invasion followed by branch migration 
leads to the formation of the Holliday junction, which in turn degrades the resolvases such as 
RuvC. The ligase will eventually glue the ends of the recombinant DNA molecule. 
 HR mechanism can also follow a different repair pathway that do not results in 
Holliday junction, but rather leads to single-strand annealing (SSA). The M/R/N-complex will 
continue to remove nucleotides in the 5’ → 3’ direction until the homologous end. RAD52 or 
RecA would then ensure that the homologous sequences are matched so that the strands can 
be ligated. This repair pathway will, in contrast to the "regular" HR repair, lead to loss of 
some parts of the sequence (Sancar et al. 2004). 
 Homologous recombination (HR) is involved in DSB repair damaged, replication-fork 
rescue, segregation of homologous in meiosis, and telomere maintenance (Sung and Klein 
2006). Although only 10 % of DSBs are repaired by this pathway in mammals, defects in the 
HR machinery can lead to serious medical disorders like the human syndromes AT-like 
disorder (ATLD) and Nijmegen breakage syndrome (NBS) (Thompson and Schild 
2002;Hakem 2008). 
1.2.7.2 Non-homologous end-joining 
 NHEJ is initiated when the proteins KU70 and KU80, which serves as a heterodimer, 
binds to DNA ends. The proteins then recruit the regulatory subunit, DNA-PKCS, so it can 
also bind to the KU-proteins. The M/R/N-complex helps to recruit XRCC4 forming a 
complex with ligase IV which links the DNA ends together, see Figure 1.3B (Sancar et al. 
2004). 
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Figure 1.3. Homologous recombination and non-homologous end-joining. A) The illustration 
shows the way of repairing a double-strand breaks, which either leads to a Holliday junction or a 
single-strand annealing. B) Schematic representation of non-homologous end-joining (Sancar et al. 
2004). 
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1.3 Endonuclease V 
 Endonuclease V (EndoV) belongs to a large group of homologous proteins, conserved 
from prokaryotes to human (see Appendix III for multiple sequence alignment). In 
prokaryotes, EndoV has a specific affinity for deaminated DNA bases, and initiates nucleotide 
incision repair (NIR). The role of EndoV in higher organisms is less known, but the data 
obtained from studies of EndoV in simple organisms provides a starting point for examination 
of mammalian and specifically human ENDOV, which has been the topic of this master 
thesis.  
 Prokaryotic EndoV 1.3.1
1.3.1.1 Endonuclease V from Escherichia coli 
E. coli EndoV (EcEndoV) is the main repair enzyme of deaminated bases in E. coli cells 
(Weiss 2008). The gene that is encoding for EndoV, nfi (endonuclease five), was 
characterized by Gates and Linn in 1977, where they found that the enzyme had substrate 
specificity for uracil in DNA  (Gates and Linn 1977;Guo et al. 1997). EcEndoV’s main 
substrate is deaminated adenine, hypoxanthine, but the enzyme also recognizes other 
deamination products like xanthine and uracil. It is known that EcEndoV recognizes abasic 
site, urea residues, hairpins, unpaired loops, tetrahydrofuran (THF), different types of flaps, 
and pseudo-Y DNA structures (Yao et al. 1994;Yao and Kow 1996;Yao and Wah-Kow 
1997;He et al. 2000). The protein initiates repair by creating a nick at the second 
phosphodiester bond at the 3’ lesion, that will result in 3’-hydroxyl and 5’-phosphoryl groups 
(Guo et al. 1997).The nick will not remove the damage DNA, so proteins have to complete 
the repair pathway. No known proteins have been identified or characterized, however it is 
assumed that the EndoV incision is followed by an exonuclease, polymerase, and ligase 
activity (He et al. 2000). Figure 1.4 shows the suggested pathway for deaminated purines. 
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Figure 1.4. Scheme for the proposed repair pathway of deaminated purine in E. coli (He et al. 
2000). EndoV nicks the second phosphodiester bond 3’ to the deaminated deoxyguanosine (xanthine, 
X) or deaminated deoxyadenosine (inosine, I) lesion. The nicked DNA is processed by an unknown 
3`-5` exonuclease, creating a single-stranded gap. DNA polymerase I synthesises the correct piece of 
DNA and ligase ligates the DNA. N = general nucleotide. 
 
 The affinity to hypoxanthine lesions for EndoV is 20 times higher than mismatches, 
and EndoV cleaves both single-stranded and double-stranded hypoxanthine-containing DNA 
(Yao and Wah-Kow 1997). It has been shown that the enzyme specificity towards mismatches 
are reduced if G:C or C:G base pairs are located close to the lesion. The specificity towards 
hypoxanthine is not affected by this, implying that Endo V has different binding interactions 
with DNA depending on which lesion is present (Yao and Wah-Kow 1997;Kow 2002). 
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1.3.1.2 Endonuclease V from Thermotoga maritima 
 Thermotoga maritima EndoV (TmaEndoV) has been found to have the same 
endonucleolytic activity of deaminated DNA bases as EcEndoV. Both TmaEndoV and 
EcEndoV require a metal ion (Mg
2+
 or Ca
2+
) to reach optimal affinity for inosine. There has 
been suggested that the 6-keto group in inosine and xanthine, and the 4-keto group in uracil 
interact with the protein which may create a local distortion in the DNA helix which can help 
recruit EndoV (Huang et al. 2001). Structural studies of TmaEndoV in complex with a 
hypoxanthine-containing DNA duplex revealed the molecular details of the interaction 
between the protein and the DNA. TmaEndoV is a αβα globular protein with an RNase H-like 
motif also found in E. coli RNase H (Dalhus et al. 2009). Dalhus et al. have shown the 
mechanism for how TmaEndoV initiates the repair of hypoxanthine in DNA. TmaEndoV 
contains a damage recognition "pocket" that can distinguish between undamaged and 
damaged bases. The enzyme also has a well-conserved sequence motif, PYIP (Pro79-Tyr80-
Ile81-Pro82). PYIP motif separates the two DNA strands and pushes the residue on the 
complementary strand partially out of the protein-DNA complex. The hypoxanthine base is 
rotated around 90° between the side chains of Leu85 and Leu142 (Dalhus et al. 2009).  
 Eukaryotic EndoV 1.3.2
 EndoV was first discovered and characterized in prokaryotes, but the search for 
homologues in eukaryotes started early. Yao and Kow came with the hypothesis that the yeast 
RTH1 nuclease and the human and murine FEN1 might be the EndoV functional homologues 
in Saccharomyces cerevisiae (Yao and Kow 1996). EndoV was later characterized as a highly 
conserved protein in higher organisms (Aravind et al. 1999;Feng et al. 2005).  
1.3.2.1 Endonuclease V from Mus musculus 
 Moe and her co-workers started with a search in the database for expressed sequence 
tags (ESTs) using EcEndoV as query, from this search Mus musculus EndoV (mEndoV) was 
identified (Moe et al. 2003). This study showed that mEndoV had a weak endonuclease 
activity of hypoxanthine in the DNA. The activity of mEndoV towards double-stranded 
substrate was higher than for the single-stranded substrate, but no other robust enzyme 
activities have been found so far. Mouse cDNA from EndoV is cloned in E. coli cells and 
found to be expressed in various tissues (Moe et al. 2003). 
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1.3.2.2 Endonuclease V from Homo sapiens 
 The gene for human Endonuclease V (hENDOV) is found in the human EST database 
by Moe et al. (Moe et al. 2003). From this human EST database many different isoforms of 
the protein were found, probably representing incomplete and uncorrected sequences from 
high-throughput DNA sequencing. 
 
1.4 Mouse as a model organism 
 Model organisms are widely used for the different opportunity to mutate individual 
genes and study the effects. This can be done either by site specific gene-targeting or by 
random mutagenesis.  For random mutagenesis, subsequent identification of the targeted 
allele is required. One of the original models for molecular biology was the bacterium E .coli, 
while several bacterial viruses (bacteriophages such as Lambda and T4) have been vital for 
the study of gene structure and regulation (Fields and Johnston 2005).  
 In eukaryotes, a number of yeast species, particularly S. cerevisiae, have been 
extensively studied in genetics and cell biology, mainly because they are quick and easy to 
grow. The fruit fly Drosophila melanogaster is commonly used, due to its rapid life cycle, 
and various visible hereditary traits (Fitzgerald-Hayes and Reichsman 2010). The roundworm 
Caenorhabditis elegans has defined development patterns, and can quickly be examined for 
abnormalities (Fields and Johnston 2005). The list of model organism also includes plant 
(Arabidopsis thaliana) and fish (zebrafish; Brachydanio rerio).  
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 The household mouse (Mus musculus) had been used as a model organism for nearly 
35 years and numerous experiments have been conducted with this small mammal. These 
experiments have contributed significantly to our knowledge of mammalian biology, 
development and pathology. The mouse and human genomes mouse models have 
approximately the same size, contain the same number of genes and show extensive synteny 
(conserved gene order) (Pennacchio 2003). Mutations that cause diseases in humans often 
cause similar diseases in mice. Importantly, mice have genes that are not represented in other 
animal models (the fruit fly and roundworm), including the genes of the immune system 
(Alberts et al. 2008). A principal strategy employed by scientists today is to convert analytical 
data from DNA sequence information into knowledge about functional processes. Functional 
analysis of mammalian gene in vivo is primarily achieved by the analysis of knockout mice 
(Chan et al. 2007). Considerable information about genes involved in the regulation of 
embryo development and pathophysiology has emerged from the use of transgenic technology 
over recent years.  
 The deletion of a gene in a mouse is referred to as a knockout mouse. A knockout 
mouse deficient in a particular gene – the gene of interest – is created by the introduction of a 
deletion-construct into embryonic stem (ES) cells in vitro. The deletion construct is able to 
integrate into the ES cell genome by homologous recombination. The ES cells that contain the 
deletion-construct in the genome are microinjected into host blastocysts to produce ES cell-
mouse chimeras, which are recognizable by their variegated coat colour at birth. Chimeras are 
bred to obtain offspring with the deletion introduced into the germline. 
 The knockout mice may not have any obvious phenotype, which might be due to 
genetic redundancy, nature of the knockout alleles, or genetic background effects. For other 
genes, the mutants die in utero owing to the critical roles of these genes in embryonic 
development (Chan et al. 2007). To overcome embryonic lethality and obtain more precisely 
controlled gene expression in a spatiotemporal manner, conditional knockout approaches have 
been developed (Bockamp et al. 2002). 
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1.5 Aim of the study 
 Prokaryotic EndoV has been shown to bind to and initiate repair of different DNA 
lesions, through the nucleotide incision pathway. The protein is an endonuclease, and is most 
effective on its main substrate hypoxanthine. An RNase H-like motif similar to a motif in the 
Holliday junction resolvase RuvC has been identified as an important part of EndoV, and it 
can thus be speculated if EndoV has a role in genetic recombination. The ENDOV homologue 
in human has been identified, and has high sequence conservation with the prokaryotic forms. 
However, no characterisation of human Endonuclease V is published. Since all key residues 
responsible for DNA binding and catalysis in prokaryotic EndoV seem to be conserved, a 
study of hENDOV would be of great interest.  
Recently, several isoforms of hENDOV have been experimentally confirmed in our 
laboratory by the sequencing of a human fibroblast cDNA library. The exon boundaries have 
been found, and some isoforms were selected as the most probable representative forms of 
hENDOV. NCBI Reference Sequence (RefSeq) annotates three representative transcripts the 
Homo sapiens locus FLJ35220, encoding hENDOV: NM_173627.3, NM_001164637.1 and 
NM_001164638.1.  
The aim of the study was to characterize the Endonuclease V from human (Homo sapiens) 
and mouse (Mus musculus). Since several isoforms of hENDOV exist, we wanted to look at 
the expression of the different transcripts variants of hENDOV in the human cells. 
Furthermore, we wanted to study the intracellular localization of hENDOV by GFP-fusion 
protein analysis. Together with Professor A. Klungland and his group at the same department, 
we wanted to study the phenotype of mice in which the mEndoV gene has been knocked out. 
This knocked out mouse already exists in the laboratory. 
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2 Materials 
2.1 Reagents 
 Chemicals 2.1.1
Chemicals Supplier 
Acetic acid MERCK 
Bacto Agar  Difco 
Bacto-tryptone Difco 
Bacto yeast extract Difco 
BioRad Protein Assay BioRad 
Boric acid MERCK 
Bovine Serum Albumin (BSA) BioLabs
®
 Inc. 
Difco Luria Bertani (LB)-Broth Difco 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Dithiotheritol (DTT) Sigma Aldrich 
DNA Loading Dye Solution (6x)  Fermentas 
dNTP Mix, AB-0196 Pharmacia 
Dulbecco`s Modified Eagle Medium with 4.5 g/l Glucose (DMEM) Lonza BioWhittaker 
Ethanol 100% Kemityl 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
Fetal Bovine Serum (FBS) PAA Laboratories GmbH 
GlutaMAX
TM
 Gibco 
Glycerol Sigma Aldrich 
Glycine MERCK 
Hydrochloric acid fuming 37% (HCl) MERCK 
IPEGAL
® 
CA-630 Sigma Aldrich 
Isopropanol MERCK 
Kanamycin Sigma Aldrich 
Magnesium chloride (MgCl2) MERCK 
Methanol VWR 
Methyl methane sulfonate (MMS) Sigma Aldrich 
MTT, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide Sigma Aldrich 
NuPAGE
®
 LDS Sample Buffer 4x Life Technologies 
NuPAGE
®
 MOPS SDS Running Buffer 20x Life Technologies 
Penicillin-streptomycin (Pen-Strep) Lonza BioWhittaker 
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich 
Phosphate buffered saline (PBS) Buffer 10x Sigma Aldrich 
Potassium chloride (KCl) MERCK 
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Chemicals Supplier 
Protease Inhibitor Cocktail, P8340 Sigma Aldrich 
Skim milk Powder Fluka 
Sodium chloride (NaCl) Sigma Aldrich 
Sodium Deoxy cholate (DOC) Sigma Aldrich 
Sodium dodecyl sulphate (SDS) Sigma Aldrich 
Sodium hydroxide (NaOH) MERCK 
SYBR
®
 Safe DNA gel stain Life Technologies 
Tris Base Sigma Aldrich 
Tris-HCl (pH 8.0) Sigma Aldrich 
Triton X-100 Sigma Aldrich 
Trypan Blue Stain Life Technologies 
Trypsin-EDTA Lonza BioWhittaker 
Tween
®
20 Sigma Aldrich 
UltraPure
TM
 Agarose Life Technologies 
 
2.2 Biological materials 
 Bacterial strains  2.2.1
Strain Characterstics Genotype Reference 
ER2566 E. coli F
-
 λ- fhuA2 [lon] ompT lacZ::T7 
gene 1 gal sulA11 Δ(mcrC-
mrr)114::IS10 
New England Biolabs 
DH5α
™
-T1
R
 E. coli F- φ80lacZΔM15 Δ(lacZYA-
argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 
thi-1 gyrA96 relA1 tonA 
Life Technologies 
 
 Cell types 2.2.2
Cell type Description Reference 
HeLa-S3 Human cervical carcinoma ATCC 
HaCaT Human immortalized keratinocytes ATCC 
Early transformed MEF WT Mouse embryonic fibroblast, mEndoV +/+ From our laboratory 
Early transformed MEF KO Mouse embryonic fibroblast, mEndoV -/- From our laboratory 
Primary MEF WT Mouse embryonic fibroblast, mEndoV +/+ From our laboratory 
Primary MEF KO Mouse embryonic fibroblast, mEndoV -/- From our laboratory 
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 Plasmids 2.2.3
Plasmid Characteristics Reference 
pEGFP-N1 N-terminal EGFP-tag  Clontech 
pEGFP-C1 C-terminal EGFP-tag Clontech 
pEGFP-transcript 1 hENDOV with exon3 and short exon9 +exon10 This study 
pEGFP-transcript 2 hENDOV without exon3 and with short exon9 + exon10 This study 
pEGFP-transcript 3 hENDOV without exon3 and with full length exon9 This study 
 
 Antibodies 2.2.4
Antibody Host Dilution Manufacturer 
Anti-hEndo V, PP132 Rabbit 1:1000 Eurogentec 
Anti-hEndo V, GP132 Rabbit 1:1000 Eurogentec 
Anti-hEndo V, SAB132 Rabbit 1:1000 Eurogentec 
Anti-hEndo V, GP133 Rabbit 1:1000 Eurogentec 
Anti-hEndo V, SAB133 Rabbit 1:1000 Eurogentec 
Anti-GFP (B-2): sc-9996 Mouse 1:1000 Santa Cruz Biotechnology 
Anti-FLJ35220, ab69400 Mouse 1:1000 Abcam 
Fibrillarin antibody, ab4566 Mouse 1:100 Abcam 
Rabbit anti-Goat IgG H&L 
(Biotin), ab 6740 
Rabbit 1:20 000  Abcam 
Goat anti-mouse antibody 
conjugated to HRP,  
115-036-068 
Mouse 1:30 000 Jackson ImmunoResearch 
Alexa Fluor® 594 Goat 
Anti-Mouse IgG (H+L), 
A11005 
Mouse 1: 1000 Life Technologies 
Protein A/G PLUS-Agarose: 
sc-2003 
- - Santa Cruz Biotechnology 
 
 Enzymes and buffers 2.2.5
Enzyme Supplier 
EcoRI New England Biolabs 
NEBuffer EcoRI (10x) New England Biolabs 
AmpliTaq Gold
®
 DNA Polymerase Applied Biosystems 
Reaction 10x buffer II Applied Biosystems 
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 Primers 2.2.6
“f” (forward) and “r” (reverse). 
Primer ID Sequence 5’→ 3’ Description 
650 TAATACGACTCACTATAGG T7 promotor 
4890 CAGGAAACAGCTATGA M13 (r)  
4891 GTAAAACGACGGCCAG M13 (f) 
13253 CCTTCTTGTGGATGGAAACGGGGTAC GSP2 (f) 
13254 GTCGTGGCTCCTCAGGGCCATTC GSP1 (r) 
AP1 CCATCCTAATACGACTCACTATAGGGC Adaptor primer 1 
AP2 ACTCACTATAGGGCTCGAGCGGC Adaptor primer 2 
13708 GCCACCTTGGCGTCCTTACAGACC Nested primer 2 (f) 
13709 CTCCCAGCAGAGGGAATGAGTCTCC Nested primer 1 (r) 
13735 GTGCTTCCCTGGTGGTGC exon3 (f) 
13737 GCCAGGAAGCCCGACACGTAGG exon3 (r) 
13738 TCGGGGGCGTTGACGTG Δexon3 (f) 
13739 CCACAAGAAGGACCTCGAG Δexon3 (r) 
13740 GCATGCCCCAAAGGAGACT Full length exon9 (f) 
13741 TGCTCCTGGGAGCCTGG Full length exon9 (r) 
13742 CAAGTCGCTGGGACTCCC short exon9 + exon10 (f) 
13743 TCAACAAAGTGCTGAGGACTC short exon9 + exon10 (r) 
 
2.3 Other materials 
 Molecular Markers 2.3.1
Standard Manufacturer 
SeeBlue
®
 Plus2 Pre-Stained Standard Life Technologies 
GeneRuler
TM
 DNA Ladder Mix Thermo Scientific 
 
 Kits 2.3.2
Kit Manufacturer 
Qiagen Plasmid Midi Kit Qiagen 
Qiagen Plasmid Mini Kit Qiagen 
Immun-Star
TM
 WesternC
TM 
Kit BioRad 
TOPO
®
 TA Cloning
®
 Kit with One Shot
®
 MAX 
Efficiency™ DH5α-T1R E. coli 
Life Technologies 
FuGENE
® 
6 Transfection Reagent Roche 
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2.4 Equipment and instruments 
 Technical equipment 2.4.1
Device Model Supplier 
Centrifuge Allegra
™
 X-22 Centrifuge Bechman Coulter 
 Spectrafuge mini Labnet 
 Spectrafuge maxi Hitachi 
 Magefuge Heraeus 
Spectrophotometer UV-visible spectrophotometer UV-160 I Shimadzu 
 NanoDrop ND-1000 Thermo Scientific 
 Wallac Victor
2
 1420 multilabel counter Wallac 
Incubator Innova 400 incubator shaker New Brunswic scientific 
 Innova 4300 incubator shaker New Brunswic scientific 
 Termaks incubator Termaks 
 Forma Steri-cycle CO2 Thermo Scientific 
 Waterbath KeboLab AS 
Power supply  Electrophoresis constant Amersham Biosciences 
 Power supply EPS 60  Pharmacia biotech. 
 Power supply ECPS 3000/150s Pharmacia biotech. 
PCR machine PTC-200 Peltier Therrmal Cycler MJ research 
Sterile hood Holten Lamin air Holten 
Imager Alphamager Alpha Innotech 
 BioRad Molecular Imager PhosphorImager  BioRad 
Sequencing machine 3730 DNA Analyzer (48 capilary) Hitachi 
Confocal 
microscopy 
LSM 510 Carl Zeiss 
Sonicator LabSonic
™
 M Sartorius Stedim Biotech 
Weighing scale AT261 Delta Range Amersham Biosciences 
 BR 4100 Amersham Biosciences 
   
Various Countess
™
 Automated Cell Counter Life Technologies  
 Countess™ cell counting chamber slide Life Technologies  
 iBlot
®
 Gel Transfer Device Life Technologies  
 iBlot
®
 Transfer Stack, PVDF Regular Life Technologies  
 NuPAGE
®
 12 % Bis-Tris-gel  Life Technologies  
 Nuclon
™
 T-25, T-75, and T-175 cm
2
, filter cap Thermo Scientific 
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 Software 2.4.2
Software Source 
Image Lab BioRad 
Wallac 1420 Manager Wallac 
NCBI Blast NCBI 
Zeiss AIM 4.2 Carl Zeiss 
Zeiss LMS Image Browser Carl Zeiss 
 
2.5 Recipes 
 Solutions and buffers 2.5.1
Solution and buffers Compostion 
RIPA lysis buffer 150 mM NaCl 
1 % IPEGAL
®
 CA-630 
0.5 % DOC 
0.1 % SDS 
1 mM PMSF 
2x Sample buffer 2x NuPAGE
®
 LDS Sample buffer 
20 mM DTT 
PBS-T 1xPBS 
0.05 % Tween
® 
Blocking buffer 5 % Skim Milk Powder in 1xPBS 
1xTBE 90 mM Tris base 
90 mM Boric acid 
2 mM EDTA (pH 8.0) 
1 % Agarose 0.5 g Agarose 
50 ml 0.5 x TBE 
1.5 µl SYBR Safe 
MTT solution 5 mg/ml MTT in 1xPBS 
Solubilization solution  10 % SDS in 0.01 M HCl 
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3 Methods 
3.1 General methods used for molecular biology 
 Miniprep and Maxiprep for plasmid purification 3.1.1
Isolation of plasmid DNA was done with Qiagen
®
 Plasmid Mini kit and Midi kit. The method 
is based on the use of anion exchange columns where the column material containing 
diethylaminoethanol binds to the negatively charged phosphates of DNA. Impurities such as 
RNA and proteins are removed with a buffer. (Qiagen
®
 2005). 
The procedure was taken from Qiagen
® 
Plasmid Purification Handbook, November 2005, 
third edition. 
 Subcloning 3.1.2
The DNA was digested with EcoRI enzyme to verify the subcloning procedure (Section 3.2.1) 
and separated on 1 % (w/v) TBE-agarose gel. The DNA fragments of interest were purified 
using QIAEX II gel extraction kit (Qiagen) following the manufacturer’s instructions. 
Concentrations were measured with NanoDrop ND-1000 Spectrophotometer (Thermo 
Scientific). 
 
3.2 5’RACE and 3’RACE experiments 
Marathon-Ready
™
 cDNAs (Clontech) are tissue-specific pools of cDNA ready for use in 
5’RACE and 3’RACE PCR. Each Marathon-Ready
™
 cDNA is synthesized from high-quality 
Premium Poly A
+
 RNA and ligated to the Marathon Adaptor. A sets of gene-specific 5’ and 3’ 
ends primers against hENDOV and adaptor primer 1 (AP1) were used to amplify a RACE 
products from cDNA pool from human brain (Clontech). After sequencing of the RACE 
products, a complete full-length cDNA clone can be obtained by end-to-end PCR. 
The standard PCR program and reaction concentrations used is listed below in Table 3.1. If 
more than one PCR-reaction was made, a master mix containing the polymerase, dNTP, PCR-
buffer and water was made giving more precise concentrations in the mix. 
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Table 3.1 Standard PCR program with AmpliTaq Gold
®
DNA Polymerase.
*Annealing temperatures should be chosen to match the Tm values of the primer pair. 
 
 
 
 
 
  
 TOPO-TA cloning 3.2.1
The 3.9 kb pCR
®
2.1 cloning vector following the TOPO
®
 TA Cloning
®
 Kits (Life 
Technologies) were used to subclone the RACE products of Marathon-Ready
™
 cDNA from 
brain for validation by sequencing. The plasmid is linearized and contains cohesive 5’ ends 
(Figure 3.1) with a thymidine overhang allowing for easy insertion of PCR fragments 
amplified with AmpliTaq Gold
®
 polymerase, which leave adenine overhangs on amplified 
fragments. A blunt end DNA fragment that does not contain adenine overhangs can be 
incubated with AmpliTaq Gold
®
 polymerase for addition of these. The fragment with adenine 
overhangs should be used for TOPO-TA cloning within 24 hours as the 3’ overhangs 
degenerate. The ligation into this backbone and transformation into competent E. coli is 
carried out as described in the manufacturer’s instructions. The DNA sequencing was carried 
in our own sequencing department.  K.
 
Figure 3.1 Linearized TOPO-TA cloning vector for insertion of fragments with adenine 
overhang. 
2.5 µl 10x buffer II 
2.0 µl dNTP 
3.0 µl MgCl2 (25 mM) 
1.0 µl Primer Fv (10 µM) 
1.0 µl Primer Rv (10 µM) 
0.3 µl AmpliTaq Gold® DNA Polymerase 
5.0 µl cDNA 
10.2 µl MQ H2O 
25 µl Total volum 
T [ºC]  Time   
95 9 min  
95 30 sec 
Repeat 
30 times 
65* 30 sec 
72 1 min 
72 5 min  
4 Hold   
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3.3 Standard cell culture procedures 
 Subculture and maintenance of cell lines 3.3.1
To prevent contamination, cell culture work was performed in laminar air flow hoods (LAF-
hood) using sterile techniques. The cell lines were grown in DMEM/F-12 medium containing 
L-glutamine (Lonza BioWhittaker). Additional supplements of fetal calf serum (PAA) 
(respectively, 10 % for the HeLa-S3 and HaCaT, and 15 % for the early transformed and 
primary MEF mEndoV +/+ and mEndoV -/- cell lines), 100 U/ml penicillin and 100 U/ml 
streptomycin (Penicillin-Streptomycin solution, Lonza BioWhittaker), and 1x GlutaMAX™-I 
(Gibco) were added to make complete growth medium (this composition will from now on be 
referred to as “medium”). The cells were grown in sterile Nunclon flasks with filter caps, T-
25, T-75, and T- 175 (cm
2
 of surface area) and incubated at 37ºC in humid atmosphere with 
5% CO2, from now on referred to as “incubation”. 
 Subculture of adherent cell lines 3.3.2
Procedure: 
1. The cell medium was removed from the primary culture and washed with 5 ml 37°C 
1xPBS to remove any residual fetal calf serum which may inhibit the action of trypsin. 
2. 1 ml preheated trypsin-EDTA (Lonza BioWhittaker) was added to the culture flask 
and incubated for about 5 minutes. 
3. The cell culture was monitored under a light microscope to visualize the detachment 
process. 
4. 9 ml fresh medium was added to the culture to neutralize the trypsin-EDTA. The cell 
suspension was flushed against the flask bottom until all cell clumps were dispersed 
and loosely attached cells were detached. 
5. A fraction of the cell suspension was transferred to a new culture flask containing 
different amounts of fresh medium. The total amount in each T-75 culture flask was 
18 ml. The subcultivation ratio was 1:10 and 1:20 for HeLa-S3 and HaCaT cell line 
and 1:10 for MEF cell lines. 
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 Viable cell quantification 3.3.3
Before every experiment, the cells were detached from the culture flask by trypsin-EDTA and 
counted to ensure reproducibility. A small volume of the mixed cell suspension was counted 
to find the correct cell number. Cell counting was performed visually by using The Countess
®
 
Automated Cell Counter (Life Tecnoloiges). 
Procedure: 10 µl of the cell sample is mixed with 10 µl supplied trypan blue and loaded to a 
Countess™ cell counting chamber slide. The camera acquires cell images from the sample on 
the slide and the image analysis software automatically analyzes acquired cell images, and 
measures cell count and viability using the trypan blue stain.  
 Transient transfection of HeLa-S3 cell line 3.3.4
The cells were transfected with the plasmids: pEGFP-N1, pEGFP-transcript 1, pEGFP-
transcript 2, and pEGFP-transcript 3 (Section 2.2.3). The following protocol is for 10 cm dish 
(medium: 10 ml).  
Procedure: 
1. FuGENE6 (Roche) was added to the cells in a 3:1 ratio to DNA (10 µg DNA with 30 
µl FuGENE6 for 100 mm dishes). 
a. The FuGENE6 was diluted in serum free medium (30 µl FuGENE6 in 70 µl medium 
for each transfection) mixed gently and incubated for 5 min at room temperature (RT). 
b. 10 µg DNA was added to the FuGENE6/medium and the tube was flicked and 
incubated for 15-20 min at RT. 
c. The transfection reagent was added to the cells in a drop-wise manner to ensure 
distribution over the entire plate surface.  
2. The cells were harvested 24 hour after the transfection. 
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3.4 Immunoprecipitation (IP) of hENDOV 
Analyses of target proteins can be done by specifically purification with corresponding 
antibody  
 Preparation of cell lysates 3.4.1
Procedure: 
1. The cells were harvested cells from four 80 % confluent T-175 flasks of HeLa-S3 and 
HaCaT. 
2. The HeLa-S3, HaCaT, and transient transfected HeLa-S3 (Section 3.3.4) cells were 
washed once with ice-cold 1xPBS and spun down at 2000 g, for 5 minutes. 
3. 1 ml of ice-cold RIPA lysis buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% IPEGAL
®
 
CA-630, 0.5% DOC, 0.1 % SDS, 1 mM PMSF, and 1 mM protease inhibitor cocktail, 
P830 (Sigma Aldrich)) were added to the cell pellets. 
4. The cells were sonicated on ice for 2x20 sec. 
5. All the samples were then spun down at 12.000 g, 4°C, for 10 minutes. The 
supernatants were transferred to fresh tubes and snap frozen in nitrogen. All the cell 
lysates were stored at -80°C until needed. 
3.4.1.1 Determination of protein concentration 
The protein concentrations from all cell lysate were the measured by Bradford Protein Assay 
(Bio-Rad) using a UV-visible Spectrophotometer UV-160 I (Shimadzu) at OD595. 
 Immunoprecipitation of hENDOV protein in cell lysates  3.4.2
Protocol: 
Lysate preparation: 50 μl A/G-coupled agarose beads (Santa Cruz Biotechnology, sc-2001) 
per immunoprecipitation was blocked with 5% BSA (w/v) in RIPA lysis buffer for 1 hour 
rotating at 4°C. The beads were then washed 2x5 minutes in RIPA lysis buffer. The beads 
were resuspended to 50 % slurry in RIPA lysis buffer without PMSF and protease inhibitor 
cocktail. 2 mg of HeLa-S3 and HaCaT cell lysates were diluted in 1 ml RIPA lysis buffer and 
added with 1 µg of anti-hENDOV (Abcam, anti-FLJ35220). 60 µg of the four EGFP cell 
lysates from HeLa-S3 were also diluted in 1 ml RIPA lysis buffer and added 1 µg anti-
hENDOV from Abcam. The mixtures were let to rotate for 1 hour. 
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Immunoprecipitation (IP): 50 μl of the 50 % slurry A/G-coupled agarose beads were added to 
each aliquot and rotated at 4°C for 1 hour. The mixtures were centrifuged briefly to collect 
beads and the lysate was discarded. The coated beads were washed in RIPA lysis buffer 3x5 
minutes and once with 50 mM Tris pH 8.0 with rotation at 4ºC. 20 µl of 2x Sample buffer (10 
µl NuPAGE
®
 LDS Sample Buffer (4X) (Life Technologies), 4 µl 1 M DTT, and 6 µl MQ 
H2O) were added to pellets and boiled at 95º C for 5 minutes. The supernatants were carefully 
collected and load onto a NuPAGE
®
 12 % Bis-Tris gel (Life Technologies). Alternatively, the 
supernatant samples were collected, transferred to clean tube and frozen at -80º C for later 
use. The frozen supernatants were reboiled for 5 minutes prior to loading on a gel. 
 Protein analysis by SDS-PAGE and Western blotting 3.4.3
Western blot is a method developed to detect specific proteins in a lysate by using a primary 
antibody specific for the protein of interest and using a standard secondary antibody to detect 
the primary antibody for visualization on the membrane. The presence of sodium dodecyl 
sulphate (SDS) denatures the proteins and supplies a negative charge that is proportional to 
the number of amino acids and therefore allows for spreading of proteins by size during 
electrophoresis (Shapiro and Shiuey 1969). 
 
SDS-PAGE gel electrophoresis protocol: Samples of recombinant hENDOV FL protein (25 
ng and 50 ng) and cell lysates from HeLa-S3 and HaCaT (2 mg) that had not been 
immunoprecipitation were mixed with 2.5 µl NuPAGE LDS Sample Buffer (4X), 1.0 µl 1 M 
DDT and MQ H2O to a total volume of ~10 μl. All the solutions were denatured at 95°C for 5 
minutes, before they were applied to a 12% NuPAGE gel with NuPAGE MOPS (1X) buffer. 
5 μl SeeBlue Plus2 Pre-Stained Standard (Life Technologies) was used as a marker. 20 µl of 
the samples that had been immunoprecipitation were loaded slowly to the bottom of the wells. 
Electrophoresis was performed: 150V for 40-60 minutes. 
Protein blotting-Western blotting procedure: After gel electrophoresis were the proteins 
blotted using the iBlot
®
 Gel Transfer Device (Life Technologies) onto PVDF membranes. 
The blotting was carried out as described in the manufacturer’s instructions. 
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Antibody incubation procedure: 
1. The membrane was removed from the transfer unit and blocked with PBS-T 
containing 5 % (w/v) skim milk (Blocking buffer) for 1 hour at room temperature with 
shaking. 
2. Incubated the membrane with primary antibody against anti-hENDOV or anti-GFP 
diluted 1:1000 in blocking buffer. 
3. The membrane was washed 3x10 minutes with 15 ml PBS-T. 
4. The membrane was incubated for 1 hour at room temperature on shaker with the 
secondary antibody conjugated to HRP in blocking buffer. 
a. The membranes incubated with anti-hENDOV made by immunization of rabbit 
were incubated with rabbit anti-Goat IgG H&L (Biotin) secondary antibody 
(Abcam, ab6740) 1:30 000 dilution.  
b. The membranes incubate with anti-mouse antibody were incubated with goat 
anti-mouse antibody conjugated to HRP (Jackson ImmunoResearch, 115-036-
068) in a 1:20 000 dilution. 
5. Step 3 was repeated. 
6. The membrane was added with 1 ml/membrane of Immun-Star WesternC 
chemiluminescence developing solution (BioRad). 
7. ChemiDoc MP System (BioRad) was used to develop the membrane. 
 
3.5 Confocal microscopy for intracellular localization of hENDOV protein 
Confocal laser scanning microscopy is a method to visualize intracellular localization of 
proteins in intact cells. Because of the point scan/pinhole detection system, light contribution 
from the neighbourhood of the scanning spot in the specimen can be eliminated, allowing 
high Z-axis resolution. Fluorescence detection by sensitive photomultiplier tubes allows usage 
of filters with narrow bandpath, resulting in minimal overlap between two spectra. This is 
particularly important when demonstrating intracellular localization of protein with 
multicolour labelling. 
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 Immunocytochemistry (ICC) 3.5.1
Immunocytochemistry (ICC) is a technique used to assess the presence of a specific protein or 
antigen in cells (cultured cells, cell suspensions) by use of a specific antibody binding to the 
target, thereby allowing visualization and examination under a microscope.  
Procedure: 
Preparation of cell culture in chamber slides:  
The HeLa-S3 cell line was seeded 2.3 x 10
4
 cells/well in a final volume of 200 µl medium in 
Lab-Tek 8-well chamber slides (Nunc, 177402), and let for overnight incubation to ensure good 
attachment to the slides. 
Transient transfection of HeLa-S3 cell line: 
The cells were then transient transfected with the three pEGFP-hENDOV constructs and 
pEGFP-N1 as described in Section 3.3.4 in a 3:1 ratio to DNA (1 µg DNA with 3 µl 
FuGENE6 for the chamber slides). 
Cytotoxic effects of drugs on transient transfected cells: 
24 hours post-transfection the transient transfected cells were exposed to DNA damaging 
agents. The various DNA damage agents and concentrations are listed in Table 3.2. The cells 
were then acutely exposed for the various agents for one hour.  
 
1. The medium was removed and the drugs of interest were added to the cells diluted in 
200 µl medium.  
2. A control well containing the same volume of the dissolvent only (dimethyl sulfoxide 
(DMSO)) was added to the cells diluted in 200 µl medium. 
3. The cells were then incubated 1 hour. 
 
Table 3.2 DNA damage agents used. 
Drugs/agents Concentration  
Camptothecin (CPT) 1.0 and 2.0 µM 
Methyl methanesulfonate (MMS) 0.5 and 2.0 µM  
Mitomycin C (MMC) 0.5 and 0.75 µg/ml 
Bleomycin 5.0 and 10 µg/ml 
Gamma rations  3 and 8 Gy 
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Fixation: 
1. The medium was removed and the cells were rinsed once with PBS. 
2. Cells were then fixed with 4% paraformaldehyde in PBS for 15 min at room 
temperature, then washed twice with ice cold PBS. 
Pre-treatment and permeabilization: 
3. The samples were quenched in 20 mM glycine in PBS for 10 min at RT. 
4. Cells were then permeabilized with 0.1% Triton X-100 in PBS for 10 min at RT. 
5. The cells were then washed three times in PBS for 5 min at RT. 
Blocking and incubation: 
6. Cells were blocked with 10% FBS in PBS for 30 min at RT. 
7. The cells were incubated with mouse monoclonal anti-Fibrillarin (nucleoli marker) 
(Abcam, ab4566) diluted 1:100 in the 10 % FBS in PBS-T for 1 hour at RT or 
overnight at 4° C. 
8. The solution was decanted and the cells were washed three times in PBS, 5 minutes 
each wash. 
9. Incubated the cells with the secondary antibody Alexa Fluor 594 goat anti-mouse IgG 
(Life Technologies, A11005) diluted 1:1000 in 10 % FBS in PBS for 1 hour at RT in 
the dark.  
10. The secondary antibody solution was decanted and the slides washed three times with 
PBS for 5 min in the dark.  
Counter staining:  
11. The samples were then incubated in 1:5000 dilutions with DAPI in PBS for 3 min. 
12. Cells were then rinsed with PBS 
Mounting: 
13. The cells were mounted with a drop Mowiol medium (MERCK) to seal the coverslip 
to prevent drying and movement. 
14. Slides were stored in the dark at 4°C. 
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 Confocal laser scanning microscopy (CLSM) 3.5.2
Carl Zeiss LSM 510 CLSM was used for visualization of hENDOV protein.  
1. The system was run with Zeiss AIM 4.2. 
2. The combination of laser, barrier filters, and excitation dichroic mirrors were chosen 
to the following combination for FITC/Texas Red: laser combination: Ar488 nm + 
HeNe543 nm; barrier filters: BP 505-575 IR for channel 2, LP 560 for channel 3; 
dichroic mirror: HFT 488/543. 
3. Objective used were EC Plan-Neofluar 40x/1.30 Oil DIC M27. 
4. LMS-file format was used for image analysis and processing on Zeiss LSM Image 
Browser. The images of the cells were showed as a single view where the images 
were composed of the two channels. 
 
3.6 Cell viability as measured by the MTT-assay 
The MTT-assay (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) is a 
sensitive colorimetric assay for the measurement of cell viability and cytotoxicity. The 
assay is based on the cleavage of the yellow tetrazolium salt, MTT, to form a soluble 
blue formazan product by a mitochondrial enzyme, and the amount of formazan 
produced is directly proportional to the number of living cells, present during MTT 
exposure. Since MTT assay is a rapid convenient, and economical, it has become a very 
popular technique for quantification of viable cells in culture. This assay is also broadly 
used to measure the in vitro cytotoxic effects of drugs on cell lines (Plumb 
2004;Sylvester 2011). In this study early transformed and primary mouse embryonic 
fibroblast (MEF) mEndoV +/+ and mEndoV -/-, from now on referred to as MEF WT 
and MEF KO, respectively. 
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 MTT-assay 3.6.1
Procedure: 
1. DAY ONE: Both early transformed and primary MEF WT and KO cells were seeded 
into 96-well plates at concentrations of 3000-4000 cells/well in a volume of 100 µl 
medium. Both cell lines were left for incubation overnight to ensure good attachment 
to the plates. 
2. The cells were plated in triplicates in each plate. Additional six wells containing only 
the medium were plated for measuring the background on the medium. 
3. DAY TWO: 5 µl of drug (Table 3.3) was added to each well, and cells were incubated 
48 hours. Three additional control wells containing the same volume of the dissolvent 
only was added to the cells. 
Table 3.3 DNA damage agents used on cell viability in MEF cells. 
Drugs/agents Concentration (µM) Dissolvent 
Camptothecin (CPT) 0, 0.05, 0.1, 0.5, 1.0, 2.0, 4.0, and 6.0  Dimethyl sulfoxide (DMSO) 
Methyl methanesulfonate (MMS) 0, 50, 100, 120, 140, 180, and 200  Medium 
Mitomycin C (MMC) 0, 0.1, 0.5, 1.0, 5.0, 10, and 20 H2O MQ 
Gamma rations  0, 20, 40, and 60 Gy - 
 
4. DAY FOUR: 10 µl 5 mg/ml MTT in PBS was added to each well and the plates were 
incubated 4 hours. 
5. The cells were solubilized with 100 µl of the Solubilization solution (10 % SDS in 
0.01 M HCl) added into each well. The plates were let to incubation overnight. 
6. DAY FIVE: The absorbance was read with Wallac 1420 VICTOR
2 
spectrophotometer 
at 550 nm with a reference filter of 690 nm. 
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4 Results  
4.1 Different transcript variants of hENDOV,  
 Multiple sequence alignments of human ENDOV with EndoV from several other 
organisms from T. maritime to M. musculus have shown that EndoV is a highly conserved 
protein. Within different mammals EndoV is even more conserved (see Appendix III for 
multiple sequence alignments), all containing 9 or 10 exons. Data from the EST database 
show a variety of single-nucleotide polymorphisms (SNPs) identified in human genomes.  
(J. K. Lærdahl, unpublished data).  
 The NCBI Reference Sequence (RefSeq) annotates three representative transcripts of 
the Homo sapiens locus FLJ35220, encoding human Endonuclease V, NM_173627.3, 
NM_001164637.1, and NM_001164638.1. A presentation of all human ENDOV isoforms 
analysed in this thesis are summarized in the Table 4.1. The full DNA and protein sequences 
are listed in the Appendix I. Many different isoforms of the protein are listed in the human 
EST database
1
. However, of the three annotated human transcripts only one contains exon 3, 
suggesting that hENDOV can to be spliced differently compared to EndoV from other 
animals. 
  
Table 4.1 Presentation of human EndoV isoforms. 
Transcript name Isoform mRNA (bp)  Protein (aa) Mass (kDa) Exons present 
NM_173627.3 1 2,840 282 30.8 1-9 (short), 10 
NM_001164637.1 2 2,705 237 25.6 1, 2-9 (short), 10 
NM_001164638.1 3 1,288  264 28.5 1, 2-9 (full length) 
 
  
                                                 
1
 http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=389678 
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4.2 5’RACE and 3’RACE experiments 
5’RACE and 3’RACE experiments using Marathon-Ready
™
 cDNA from human brain 
(Clontech) was used to identify the different transcript variants of hENDOV.  
For 5’RACE reaction a gene specific primer (GSP1) located in exon 6/7 was used together 
with an outer primer (AP1) located in the adaptor at the 5’ ends of the transcripts. For the 
3’RACE reaction a gene specific primer (GSP2) located in exon 4 was used together with the 
AP1 primer located in the adaptor at the 3’ ends of the transcripts (Figure 4.1). The expected 
sizes of RACE products amplified with GPSs are shown in Table 4.2. 5’RACE and 3’RACE 
cDNA products amplified with GSPs and AP1 appeared as many bands (Figure 4.2). 
 
Figure 4.1. The cDNA template from human brain and primers used in Marathon RACE 
reaction. cDNA synthesis and adaptor ligation create a population of cDNA with the hENDOV 
structure depicted above. The exons that are represented show the different exons that are found in the 
different isoforms of hENDOV (this is a schemativ illustration where the width of the boxes aren’t 
representative of the real size of the exons). Adaptor primes (AP1 and AP2). AP2 is for analysis of 
RACE products for nested RACE PCR. Gene specific primers (GSP1 and GSP2). Nested gene specific 
primer (NGSP1 and NGSP1) can be used for characterization of RACE products for nested RACE 
PCR. 
 
Table 4.2 Size of RACE products amplified with GSPs. 
GSP products Primers Description  Size (bp) 
5’RACE AP1/13254 (GSP1) With exon 3 603 
5’RACE AP1/13254 (GSP1) Without exon 3 468 
3’RACE 13253 (GSP2)/AP1 With full length exon 9 509 
3’RACE 13253 (GSP2)/AP1 With shot exon9 and exon 10 484 
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Figure 4.2. 3’RACE and 5’RACE cDNA product amplified with gene specific primers and adaptor 
primer visualized after gel electrophoresis.  
 
Since a lot of weak bands were observed in the first RACE reaction we tried nested PCR in 
order to obtain more specific products. In nested PCR we used the first RACE reaction as a 
template for a second PCR using nested outer primer (AP2) and nested gene specific primers 
(NGSPs), downstream and upstream of the first primers as shown in Figure 4.1. The NGSP1 
primer is located in exon 6 and the NGSP2 primer is located in exon 5. The expected sizes of 
RACE products amplified with NGPSs are shown in Table 4.3. A specific band was amplified 
for nested 3’RACE PCR product, but for nested 5’RACE PCR only low molecular weight 
products were present (Figure 4.3). 
Table 4.3 Size of RACE products amplified with NGSPs. 
NGSP products Primers Description  Size (bp) 
5’RACE AP2/13709 (NGSP1) With exon 3 562 
5’RACE AP2/13709 (NGSP1) Without exon 3 427 
3’RACE 13708 (NGSP2)/AP2 With FL exon 9 562 
3’RACE 13708 (NGSP2)/AP2 With shot exon9 and exon 10 431 
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Figure 4.3. Nested 3`RACE and 5`RACE PCR products amplified with the nested gene specific 
primers and nested adaptor primers visualized after gel electrophoresis. 
 
The nested 3’RACE PCR product slightly lower than 400 bp was obtained. The product was 
excised from the gel (Section 3.1.2)  
Because no nested 5’RACE PCR product within the expected size was amplified, we decided 
to cut out two gel fragments from the first 5’RACE reaction, one fragment round 400 bp and 
the second fragment at round 600 bp, shown in the Figure 4.2. 
The isolated RACE products were subcloned into the pCR
®
2.1-TOPO vector as described in 
methods. The enzyme EcoRI was used to digest of purified plasmid DNA for verification of 
insert size. All clones showed a variation in the sizes of the bands (data not shown). The 
samples of expected size were sequenced. DNA sequences were analysed and compared with 
the hENDOV gene in: NM_173627.3, NM_001164637.1, and NM_001164638.1 listed in 
Appendix I. 
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A total of 30 clones were sequenced in which only two clones contained exon 3, 10 clones 
were partially unprocessed containing introns, and 7 were degraded (starting in exon 4 or 5). 
11 of 30 sequenced clones were lacking exon 3, were 2 and 1 of these clones were without 
exon 4 and exon 5, respectively. Based on these observations we assume that full-length 
clones of hENDOV containing exon 3 most likely are expressed at low levels in the cells. 
The specific band we obtained from nested 3’RACE PCR and subcloned into pCR
®
2.1-TOPO 
vector showed that the adaptor on 3’ end was found in the same place in exon 8 of the 5 
sequenced clones. This will not tell us whether we can find protein of hENDOV with short or 
full length exon 9 or exon 10. 
4.3 Expression analysis of the three transcript variants of hENDOV 
In order to further clarify the expression of the different transcript variants of hENDOV in the 
cell, we used cDNA isolated from ACHN cell line (obtained from Dr. Yang Mingyi) for PCR 
analysis using exon-specific primers (Section 3.2). Amplifications with of all the exon-
specific primers were successful (Figure 4.4) and shows that the exons in the three annotated 
hENDOV transcripts are present in the cells.  
 
Figure 4.4. PCR amplification of the by exon-specific primers. The PCR amplifications were used 
with specific primers for exon 3 (13735/13737), without exon 3 (13738/13739), full length exon 9 
(13740/13641), and for short exon9 + exon 10 (13742/13743). 
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4.4 Immunoprecipitation of endogenous hENDOV 
Immunoprecipitaion was conducted to examine the endogenous protein with respect to size 
(+/- exon 3) and possible post-translational modifications. First a test was run on an antibody 
made by immunization of rabbits with our purified recombinant hENDOV FL (isoform 1). 
This was done by Western blot on purified hENDOV FL protein. Serum from two different 
rabbits (rabbit 132 and 133) were used: the small bleed (PP), large bleed (GP), and the serum 
for the final bleed (SAB). The results (Figure 4.5) show that serum from GP132 had best 
binding effect and was therefore used in the further experiments. The hENDOV FL has an 
estimated size of 34 kDa. 
 
 
Figure 4.5. Test of the antibody made by immunization of rabbits on pruified hENDOV FL 
protein by Western analysis. The on purified hENDOV FL proteins is blotted onto PVDF 
membranes and probed with serum from two different rabbits (rabbit 132 and 133): the small bleed 
(PP), large bleed (GP), and the serum for the final bleed (SAB). 
 
The immunoprecipitation was conducted with protein A/G PLUS-agarose beads as described 
in methods. Lysate from HeLa-S3 and HaCaT cells were immunopresipitated using beads 
conjugated with anti-hENDOV (Abcam, anti-FLJ35220, ab69400). The precipitated material 
was run on SDS-PAGE gel, and subjected to Western analysis using the hENDOV antibodies, 
one obtained from Abcam and the antibody made by immunization of rabbit (GP132). 
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No immunoprecipitated endogenous hENDOV protein was detected with either of the two 
types of antibodies in HeLa-S3 and HaCaT cell lysates, as shown in Figure 4.6 A and B.  
   
Figure 4.6. Western analysis of immunoprescipitated endogenous hENDOV protein. Lysate from 
HeLa-S3 and HaCaT cells were immunopresipitated with beads conjugated with antibody against 
hENDOV (anti-FLJ35220). (A) The PVDF membrane was probed with anti-hENDOV obtained from 
Abcam, anti-FLJ35220. (B) This membrane is probed with the serum from rabbit, GP132. 
 
4.5 Intracellular localization of EGFP-hENDOV fusion protein 
Enhanced GFP (EGFP) is a commonly used tag to label proteins for localization studies in 
plants (Grebenok et al. 1997;Von Arnim et al. 1998), yeast (Bordonne 2000),  and mammals 
(Borghi et al. 2001;Minopoli et al. 2001;Sheng et al. 2004), e.g. to identify nuclear 
localization. 
Syntetic cDNA for Homo sapiens Endonuclease V transcript variant 1-3 was subcloned by 
Genscript in a pEGFP-C1 vector. These vectors were used to express EGFP-hENDOV fusion 
protein in HeLa-S3 cells. Transfections were carried out using FuGENE 6. Before analysis, 
cells were cultured for twenty-four hours post-transfection. The cells were then fixed with 
4 % paraformaldehyde and observed under a confocal microscope. 
This was done to monitor of how the different hENDOV isoforms of the proteins would 
localize inside the cells. All three of the pEGFP plasmids constructs and vector only  
(pEGFP-N1) were transfected into HeLa-S3 cell line. The result of cellular localization is 
shown in the Figure 4.7 below. 
A B 
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Figure 4.7. Subcellular localization of EGFP-hENDOV isoform 1-3. A triplicate representative 
panels of HeLa-S3 cells following transient transfection, as viewed by laser scanning confocal 
microscopy. (A-C) Shows cells expressing EGFP-hENDOV isoform 1 localized in the nucleus and in 
the cytoplasm, (D-F) EGFP-hENDOV isoform 2, shows only localization of the fusion protein in 
cytoplasm, (G-I) EGFP-hENDOV isoform 3 showed also only localization of the fusion protein in 
cytoplasm, and (J-L)EGFP only shows localized in the nucleus and cytoplasm of transfected cells. 
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EGFP-hENDOV isoform 1: This protein has exon 3 and a short exon 9, and exon 10 (Figure 
4.7 A-C). This construct showed localization in the nucleus and in the cytoplasm. The 
localization in the cell nucleus was at distinct compartments corresponding to nucleoli. To 
verify this localization the cells were stained with a specific antibody against fibrillarin, a 
protein found only in this compartment. Figure 4.8 shows that EGFP-hENDOV isoform 1 
protein is enriched in nucleoli as it co-localizes with fibrillarin antibody. 
 
Figure 4.8. Subcellular localization of EGFP-hENDOV isoform 1 and fibrillarin. (A) Shows the 
localization of EGFP-hENDOV in the nucleus and in the cytoplasm. (B) The cells are stained with a 
specific antibody against fibrillarin. (C) Shows a merged picture of EGFP-hENDOV isoform 1 protein 
enriched in nucleoli as it co-localizes with fibrillarin antibody. 
 
EGFP-hENDOV isoform 2: This protein is without exon 3, has a short exon 9, and exon 10 
(Figure 4.7 D-F). This isoform of hENDOV showed only localization of the fusion protein in 
cytoplasm.  
EGFP-hENDOV isoform 3: This protein is also without exon 3 and has the full length form of 
exon 9 (Figure 4.7 G-I). This showed also only localization of the fusion protein in cytoplasm.   
EGFP only (pEGFP-N1) (Figure 4.7 J-L) was localized in the nucleus and cytoplasm of 
transfected cells. 
No difference in localization pattern was seen when the GFP-tag was placed at the C-terminal 
end of the protein. These data demonstrate that full-length hENDOV with exon 3 may exert 
its function in nucleolus and possibly also in cytoplasm. The putative truncated form of 
hENDOV lacking exon 3, however, is most likely not associated with DNA 
handling/processing. 
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4.6 Western analyse GFP fusion proteins  
Western analysis was performed to confirm that the various EGFP fusion proteins were 
expressed in their full length in the cells.  
The protein analysis by SDS-PAGE and Western blotting of the transient transfected HeLa-S3 
cells overexpressing the three different EGFP fusion proteins are shown in Figure 4.9. The 
three different proteins, EGFP-hENDOV isoforms 1-3 were visualized by probing the blots 
with anti-GFP antibody. Bands of expected sizes for all proteins were detected: EGFP only 
(pEGFP-N1) (positive control, 27 kDa), EGFP-hENDOV isoform 1 (57.8 kDa), EGFP-
hENDOV isoform 2 (52.6 kDa), and for EGFP-hENDOV isoform 3 (55.5 kDa).  
 
Figure 4.9. Detection of the three different isoforms of EGFP-hENDOV HeLa-S3 cells lysates. 
SDS-PAGE gel and Western blotting of cell lysates overexpressed with the three EGFP-hENDOV 
proteins blotted onto PVDF membranes and probed with anti-GFP antibody. 
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4.7 Relocalisation of EGFP-hENDOV isoform 1 
The nucleolus (plural nucleoli) is the most active and dynamic nuclear domain that plays a 
prominent role in the organization of various components of the nucleus. The major roles of 
nucleus: ribosome biogenesis, rDNA transcription, pre-rRNA processing, and assembly for 
mature rRNAs with ribosomal proteins (Hadjiolov 1985). Nucleoli are essential in the 
formation of ribosomes that synthesize cell proteins. 
Based on the specific nucleoli localization of the EGFP-hENDOV isofrom 1 fusion protein, 
relocalisations of hENDOV after treatment of cells with DNA damaging agents were studied. 
Initially, camptothecin (CPT) which is a DNA topoisomerase I inhibitor, was chosen. CPT is 
thought to induce DSBs in a DNA replication dependent manner. 
Before analysis, cells were cultured for twenty-four hours post-transfection; the cells were 
treated with 1 µM and 2 µM CPT for 1 hour before examination under a microscope. We 
observed that the nucleoli localization was excluded from the nucleus after 1 hour with acute 
treatment of 1µM and 2 µM CPT (Figure 4.10, C and D). 
Next, the cells were treated with gamma radiation which induced clean DSBs in the DNA. 
Cells were radiated with 3 Gy and 8 Gy before fixation with 4 % paraformaldehyde. These 
acute treatments did not result in relocalisation of hENDOV in HeLa-S3 cells (Figure 4.10, E 
and F).  
Then we looked at cells treated with bleomycin which results in DSBs. The cells were 
incubated with 5µg/ml and 10µg/ml bleomycin (Figure 4.10, G and H) for 1 hour prior to 
fixation with 4 % paraformaldehyde. The next drug that was tested was Mitomycin C that 
causes alkylation damage and DNA DSBs. Cells were incubated with 0.5 µg/ml and 0.75 
µg/ml Mitomycin C (Figure 4.10, I and J). The last drug tested for relocalization of hENDOV 
isoform 1, was methyl methanesulfonate (MMS), 0.5 mM and 2.0 mM. (Figure 4.10, K and 
L) MMS can also cause alkylation damage and DSBs. Neither of the treatments results in 
relocalisation of EGFP-hENDOV isofrom 1 in transient transfected HeLa-S3 cells.  
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Figure 4.10. EGFP-hENDOV isoform 1 expressed in HeLa-S3 cells treated with different DNA 
damageing agents. (A-B) Transfected cells with DMSO (control). (C-D) Transfected cells treated 
with CPT, 1 µM and 2 µM, respectively. (E-F) Cells exposed with 3 and 8 Gy gamma radiation, (G-H) 
5 and 10 µg/ml Bleomycin, (I-J) 0.5 and 0.75 µg/ml Mitomycin C, and (K-L) 0.5 and 2.0 µM MMS. 
 
Based on the relocalization of nucleoli localization after acute treatment with CPT, we wanted 
to see if the nucleoli were intact. To verify this, cells were stained with antibody against 
fibrillarin. Confocal microscopy pictures showed that the nucleoli remained intact after the 
CPT treatment (Figure 4.11). 
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Figure 4.11. EGFP-hENDOV isoform 1 over expressed in HeLa-S3 treated with 2µM CPT. (A-
C) The cells are in incubated with DMSO, this is the solvent of CPT. (D-F) 1 hour with acute 
treatment of 2 µm CPT. 
 
4.8 Viability assay (MTT-assay) 
In our laboratory we have generated constitutive knockout mice of mEndoV from which we 
have isolated the primary mouse embryonic fibroblast (MEF) cells. Studies of MEF cells have 
played an important role in the elucidation of the molecule mechanisms underlying cellular 
immortalization, transformation, and tumorgenesis. Additionally, utilization of MEF cells 
disrupted for specific gene has provided a powerful tool to analyse the genetic regulation of 
these cellular processes (Sun and Taneja 2007). 
Viability assay was used in cytotoxicity studies to see whether we can observe a difference 
between the MEF cell lines in which the gene for mouse EndoV were intact and knocked out. 
MTT-assay technique has become a popular quantification of viable cells in culture. For each 
cell line optimal seeding concentration were tested, to obtain maximal possible absorbance 
while ensuring that cells remained in exponential growth. The cell number chosen for early 
transformed MEF (passage around 18-25) and primary MEF (passage 1-5) cells was 3000-
4000 cells/well for 5-days assay. 
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 Early transformed MEF 4.8.1
Based on the relocalization of nucleoli localization after acute treatment with CPT of EGFP-
hENDOV isoform 1 where nucleoli were excluded from the nucleus in transient transfected 
HeLa-S3 cells. We analysed the effect of CPT on viability of without MEF KO compared to 
MEF WT cells. This was done on early transformed MEF cells. Raw data for all the graphs in 
this study is listed in Appendix II. As shown in Figure 4.12, a wide variation was observed 
within the four different lines that were tested by WT and KO cell line showing that the 
transformed cell lines behaves differently. 
 
Figure 4.12. Dose response curved for the early transformed MEF WT and KO cell lines 
exposed to different doses of CPT (µM) after 48 hour incubation. (A) Shows the variation in dose 
response between the four early transformed MEF WT cell lines used in this study. (B) Shows the 
variation in dose response between the four early transformed MEF KO cell lines. 
 
An average of the viability data for the MEF WT and the KO on the early transformed cell 
lines was estimated. However no difference was seen between the cell lines with mEndoV 
gene intact and with the same cell lines with mEndoV gene knocked out (Figure 4.13). 
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Figure 4.13. The estimated average of dose response curved for comparison of the early transformed 
MEF WT and KO cell lines exposed to different does of CPT (µM) after 48 hour incubation.  
 
 Primary MEF 4.8.2
Because there was considerable variation within each early transformed MEF cell line, a 
study was also done on the corresponding primary MEF cell lines. The variation observed 
within each primary MEF cell lines is much lower compared to the early transformed MEF 
lines. This was also observed in all the five different lines that were tested by each WT and 
KO cell line (Figure 4.14). 
 
Figure 4.14. Dose response curved for the primary MEF WT and KO cell lines exposed to 
different doses of CPT (µM) after 48 hour incubation. (A) Shows the variation in dose response 
between the five primary MEF WT cell lines used in this study. (B) Shows the variation in dose 
response between the five primary MEF KO cell lines. 
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However, when the average of the viability data for the MEF WT and KO primary cell lines 
was calculated, no difference was seen between cell lines with or without mEndoV (Figure 
4.15). 
 
Figure 4.15. The estimated average of dose response curved for comparison of the primary MEF WT 
and KO cell lines exposed to different does of CPT (µM) after 48 hour incubation.  
 
 Viability assay (MTT-assay) with different DNA damaging agents 4.8.3
Since no effect was observed by exposing MEF Endo V cell lines to CPT treatment, assays 
with other agents were also performed. Cells were incubated with methyl methanesulfonate 
(MMS), Mitomycin C (MMC), and gamma radiation as described in Methods. As one can see 
from Figure 4.16-18 no difference in viability was observed between the primary MEF Endo 
V WT and KO cells when exposed to these agents. 
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Figure 4.16. The estimated average of dose response curved for comparison of the primary MEF WT 
and KO cell lines exposed to different doses of MMS (µM) after 48 hour incubation.  
 
 
Figure 4.17. The estimated average of dose response curved for comparison of the primary MEF WT 
and KO cell lines exposed to different doses of MMC (µM) after 48 hour incubation.  
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Figure 4.18. The estimated average of dose response curved for comparison of the primary MEF WT 
and KO cell lines exposed acute doses exposure gamma ratiation (Gy) after 48 hours recovery. 
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5 Discussion 
5.1 Different transcript variant of hENDOV 
 The reason for the 5’RACE and 3’RACE experiments being conducted were based on 
observations done by others in the lab where they looked at the total RNA that was purified 
from primary human fibroblasts, kidney (ACHN), and colon (HCT116) cell lines and 
subjected to cDNA synthesis and PCR analysis using exon 1 and exon 8 or exon 9-specific 
primers. They were only able to amplify hENDOV transcripts lacking exon 3. This was 
further demonstrated in 5’RACE experiments using Marathon-Ready
™
 cDNA from brain in 
which only 2 of 30 sequenced clones contained exon 3. Based on these observations we 
assume that full-length hENDOV transcript containing exon 3 most likely are expressed at low 
levels in the cells. The 3’RACE experiments gave no clarification of the hENDOV expression 
since the inserted adaptor (done by Clontech) was found in exon 8, within the area that we 
wanted to look at.  
 Of the 30 sequenced clones from the 5’RACE analysis: 10 clones were partially 
unprocessed containing introns, and 7 were degraded (starting in exon 4 or 5). A few percent 
of the population has a stop codon in exon 3. This would cause an extremely short version of 
hENDOV which would most likely be non-functional. 25 % of an Asian panel has a hENDOV 
variant with an A to G mutation just in front of exon 4. This removes the 3’splicing signal for 
intron 3, and most likely deleterious for the whole protein (J. K. Lærdahl, unpublished data). 
Many different isoforms of the protein are listed in the human EST database. This includes at 
least 31 spliced variants, indicating a highly complex locus. However, of the three annotated 
human transcripts only one contains exon 3, suggesting that hENDOV appears to be spliced 
differently compared to EndoV from other animals. 
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The expression of hENDOV transcript variant 2 (lacking exon 3) in human fibroblast cDNA 
library is confirmed by others in the laboratory. But the functions of the corresponding 
proteins are obscure since they lack exon 3, which is known to make up the core of the 
protein. The missing exon also contains the conserved PYVS motif. This motif is believed to 
act as a DNA strand-separating wedge, and is thus important for DNA binding. It would be of 
interest to test this isoform for DNA binding capability in the same way as the hENDOV 
isoform 1. Unfortunately, soluble free hENDOV isoform 2 has not been obtained, however 
optimisation to the purification protocol is on-going.  
 We were able to amplify the three annotated hENDOV transcripts with a PCR 
amplification with cDNA isolated from ACHN cells using exon 3, without exon 3, full length 
exon 9, and shot exon 9 + 10 specific primers. This shows that the transcripts are present, but 
says nothing about the quantitative amount in the cell. Due to the time aspect of this thesis, we 
did not have time to do the Real-Time qPCR to quantify the amount of the three different 
transcripts to the total level of hENDOV transcripts in normal cells.  
 
5.2 Western analysis of endogenous hENDOV 
 We could not detect endogenous hENDOV protein in the Hela-S3 and HaCaT cell 
lysates by immunoprecipitation. This might be that the level of hENDOV in these cells is too 
low to be detected with the specific antibodies.  
 There are several factors that can lead to the negative result that was obtained using 
immunoprecipitation. The ionic strength (salt concentration) or choice of detergent and pH in 
the lysis buffer may significantly affect the protein interactions and/or the structural integrity 
of the protein. Additionally, steric hindrance from the epitope area on the antibody may 
interfere with the protein interactions. Another consideration is that immunoprecipitation 
contains several wash steps and incubation periods where the protein interaction might be 
disrupted or the proteins degraded by proteases. These problems can be reduced by adding 
protease inhibitors to the lysis buffer and preforming the incubations at 4°C. 
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 Non-specific binding to the beads is a common problem. Addition of detergents such 
as Tween and Triton X-100 to the washing buffer can reduce the amount of protein that bind 
in a non-specific manner. In addition, the incubation time can be reduced and the primary 
antibody concentration can be decreased. Blocking with skimmed milk or BSA could also 
reduce the number of binding sites in the beads. 
 
5.3 Intracellular localisation 
 The cells of eukaryotic organisms are elaborately subdivided into functionally distinct 
membrane bound compartments. Some major constituents of eukaryotic cells are: 
extracellular space, cytoplasm, nucleus, mitochondria, Golgi apparatus, endoplasmic 
reticulum (ER), peroxisome, vacuoles, cytoskeleton, nucleoplasm, nucleolus, nuclear matrix 
and ribosomes.  
 The green fluorescent protein (GFP) from the jellyfish Aequorea victoria has vaulted 
from obscurity to become one of the most widely studied and exploited proteins in 
biochemistry and cell biology. The protein’s ability to generate a highly visible, efficiently 
internal fluorophore is very valuable. GFP has become well established as a marker of gene 
expression and protein targeting in intact cells and organisms (Tsien 1998). Nevertheless, 
EGFP alone is distributed in the cytoplasm and nucleus, and this can give a diffuse conclusion 
about NLS in the fusion partner (Bohm et al. 2006). 
 Intracellular localisation of a protein can provide valuable information towards 
elucidating the biological function. In this study the subcellular localization of the three 
isoforms of hENDOV fused to EGFP was investigated. However, the intranuclear localisation 
differs between the three proteins. We showed that hENDOV isoform 1 was located to the 
cytoplasm and nucleus with enrichment in nucleoli, whereas the other two proteins showed 
only localization in the cytoplasm. Cells overexpressing EGFP-hENDOV isoform 1 were 
exposed to DNA damaging agents and interestingly after CPT exposure hENDOV was 
excluded from the nucleoli. This may indicate that the nucleolus act as a storage compartment 
for hENDOV isoform 1. Since this was only observed after exposure of the CPT and not the 
other agents (MMS, MMC, and gamma radiation) it is difficult to draw an absolute 
conclusion. As this system is based on overexpression, one cannot exclude that the other 
agent also results in relocalisation of parts of the fusion protein that is match by the high 
expression level. 
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 Camptothecin is a secondary metabolite used as an anti-cancer drug that damages 
DNA, leading to the destruction of the cell. Camptothecin affects the activity of the enzyme 
topoisomerase I, whose normal action is alleviate supercoiling in DNA by cleaving, 
unwinding, and religate of the DNA. When camptothecin binds topoisomerase I, the enzyme 
will be able to cleave but not religate DNA. Thereby, camptothecin causes double-strand 
breaks in DNA (Buckwalter et al. 1996;Rubbi and Milner 2003). For the topoisomerase I-
targeted drug camptothecin, lethal DNA damage has been proposed to occur as a result of the 
interaction of the DNA replication apparatus with the drug-trapped enzyme-DNA complex 
(Nelson and Kastan 1994). 
 The role of hENDOV in the nucleoli remains unclear. The primary role of this 
subnuclear compartment is in ribosome biogenesis, although emerging evidence suggests 
additional non-ribosomal functions (Raska et al. 2006;Boisvert et al. 2007). Many proteins, 
including DNA repair proteins, have been shown to localize to the nucleoli. For some, like the 
RecQ helicases WRN and BLM, the nucleolus seems to be sequestering compartment since 
the proteins were recruited to distinct nuclear foci when cells were exposed to certain 
damaging agents (Marciniak et al. 1998;Yankiwski et al. 2000;Sanz et al. 2000;Karmakar and 
Bohr 2005;Otterlei et al. 2006). In marked contrast, the RECQL4 helicase did not relocate 
after treatment with various DNA damaging agents, but the protein accumulated in the 
nucleoli upon oxidative stress (Woo et al. 2006). Thus, the nucleolar localization clearly 
serves different functions for different proteins.  
 Nucleolar proteins like nucleolin and topoisomerase I have been describing underwent 
p53-dependent relocalisation from nucleoli after cellular stress such as heat shock and DNA 
damage, respectively (Mao et al. 2002;Daniely et al. 2002). HeLa cells, utilized in our study, 
are cancerous cells defective in p53, a protein involved in the DNA damage response and 
malfunctioning in several cancer cells. Cell lines with functional p53 protein should, 
therefore, be employed in further studies to elucidate the role of hENDOV in nucleoli.  
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 Methodological aspects 5.3.1
 To examine the intracellular localisation of the three isoforms hENDOV that was used 
in this study, we overexpressed EGFP-tagged protein in HeLa-S3 cells. When evaluating the 
result we therefore need to consider the use of a tagged protein which is present in excess 
amounts in the cells. Overexpression of proteins in cells may generate novel phenotypes. 
Increased amounts of protein can also lead to disrupted intracellular protein localisation, in 
addition to possibilities for masking relocalisation of the protein. We observed that the 
nucleoli localization was changed for hENDOV isoform 1 hour CPT treatment. Another 
problem arising when studying overexpressed proteins is that the unnatural amount of protein 
will introduce an unbalanced environment in respect to protein interactions and cellular 
response involving other proteins.  
 One advantage with tagged proteins is that they can be studied in living cells evading 
the artefacts of cell fixation and permeabilisation. However, GFP is a 27 kDa protein which 
may affect the localisation of the attached protein. New technologies are under way to solve 
these problems, of which the use of small arsenical based fluorescent compounds is one 
example (Griffin et al. 1998). 
 In this period of work I have devoted a lot of time on developing and testing 
antibodies towards human ENDOV and mouse EndoV without much success. This is a 
common problem in the DNA repair field in respect to antibodies recognising specific 
proteins. Several report on e.g. OGG1 immunocytochemistry have been published, although, 
a growing scepticism towards the specificity of the antibodies is apparent. The level of DNA 
glycosylases in cells have been proposed to be too low to be detected with antibodies, which 
may also apply to endonuclease V. 
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5.4 MTT-assay 
 In this study we used a viability assay (MTT-assay) to determine the ability of MEF 
cells to maintain or recover its viability after CPT exposure and treatment with other DNA 
damaging agents. An important step in transformation is immortalization, in which cells gain 
the ability to grow indefinitely by bypassing cellular senescence that imposes a finite number 
of divisions in culture. Primary mouse embryonic fibroblast (MEF) cells have limited growth 
capacity and on prolonged passing spontaneously immortalize at a low frequency (Sun and 
Taneja 2007). In this study we have worked with constitutive knockout mouse, mEndoV +/+ 
(WT) and mEndo -/- (KO). Others in the laboratory have isolated mouse embryonic fibroblast 
cells and with prolonged passaging spontaneously transformed the MEF cells used in this 
thesis.  
 No cytotoxic effects were obtained between MEF WT and KO cell lines after CPT 
exposure or treatment with other DNA damaging agents. We started to look at early 
transformed MEF cells, these lines showed a substantial variation in survival between 
isogenic isolates. Because of this, we decided to perform the MTT-assay on the corresponding 
primary MEF lines. These lines have not been spontaneously transformed, which could 
eliminate the variation within these cell lines. This variation was eliminated using primary 
MEF cell lines, but no cytotoxic effects were observed between the WT and KO after 
treatment with DNA damaging agents. Both WT and KO had a representable dose response to 
CPT and to the other agents, as shown in the results. Based on these observations, we can 
conclude that we found no effect of knocking out the gene for EndoV and exposing the cells 
for DNA damaging agents. This supports the theory that eukaryotic EndoV can have a 
different role than prokaryotic EndoV. 
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5.5 Constitutive or conditional knockout 
 In this study a mEndoV constitutive knockout mouse was made over a conditional 
knockout (made by Professor A. Klungland’s group at the same department). Both variants 
have drawbacks. Constructing a conditional knockout mouse is more laborious, more time-
consuming and is more expensive to produce than a constitutive knockout. The major 
drawback with the constitutive knockout is that if removal of the gene of interest, in our case 
mEndoV, leads to embryonic lethality this precludes the analysis of a potential adult 
phenotype. Other undesirable effects of the gene inactivation can be pleiotropic side effects. 
These are compensatory reactions to the introduced germ line mutation obscuring or 
preventing a clear-cut analysis. Moreover, the knocked out gene may have a function during 
early development and its invalidation might induce a highly complicated accumulative 
phenotype which does not necessarily represent solely the gene of interest (Bockamp et al. 
2002). 
Analysing the gene function at a specific developmental window or in a particular cell lineage 
might be necessary. In a constitutive knockout the targeted gene is inactivated in all cells from 
birth until death, whereas conditional knockout allows the spatiotemporal control of the gene 
silencing. Therefore, knockout can prevent unwanted pleiotropic side effects and exclude 
accumulative compensatory developmental changes from the earliest embryonic stages.  
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5.6 Final conclusions and future work 
 We are familiar with that the fact there is a high (and uncertain) number of isoforms of 
human ENDOV, which makes it difficult to characterize and determine the function of this 
protein. The RACE experiments gave no special clarifications of the hENDOV transcripts. 
This may be due to bad quality of the cDNA obtained from Clontech, since we saw that the 
adaptor was inserted in exon 8 in the 3’RACE experiments. The Real-Time qPCR technique 
can be used to quantify the amount of the total level of hENDOV transcripts in normal cells, 
which can provide a better clarification of the different hENDOV transcripts.  The full-length 
hENDOV transcript (exon 3-contaning) does not represent the majority of the transcripts 
variants in the human cells. 
 The three different transcript variants of human hENDOV were successfully subcloned 
and expressed in fusion with green fluorescent protein (GFP). The purified recombinant 
hENDOV FL was used to produce an antibody against human ENDOV by immunization of 
rabbits.  
  We showed that hENDOV isoform 1 was located to the cytoplasm and nucleus with 
enrichment in nucleoli. But the other two isoforms showed only localization in the cytoplasm. 
These isoforms may reflect different roles of human ENDOV, such as different substrates, 
cellular localization, cell-cycle dependent or organ-specific forms. There is a particular 
interest in the hENDOV isoform 2 (lacking exon 3), which that lacks central parts of the DNA 
binding and catalytic regions. Work is in progress to optimize the protein purification protocol 
for this from.  
 E. coli EndoV is known to bind to the DNA, and similar studies have been performed 
with human ENDOV. These binding studies (done by other people in the laboratory) showed 
hENDOV isoform 1 specifically bound to 3’flap, 5’flap, fork, pseudo-Y, 3-way junction, and 
4-way junction (Holliday junction) DNA. No binding was observed for inosine or A:TT loop 
DNA. This demonstrates that if hENDOV is involved in DNA repair in human cells, it would 
be differently than E. coli EndoV, of which inosine is the main substrate. hENDOV is shown 
to bind specifically to Holliday junction DNA, suggesting that it is involved in genetic 
recombination, such as a Holliday junction resolvase. This hypothesis is further supported by 
structural studies that show that prokaryotic ENDOV contain RNaseH-like motif similar to 
the Holliday junction resolvase RuvC. Multiple sequence analyses show that ENDOV is 
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highly conserved from prokaryotes to humans, and it is thus likely that hENDOV also 
contains the RNase H-like motif.  
 E. coli EndoV recognizes certain DNA damages and nicks the DNA strand 3’ of the 
lesion. hENDOV was also tested in our laboratory for endonucleolytic activity. No activity 
was found for 5’flap, 3-way junction, or 4-way junction DNA. Several different buffers were 
used, exploring different pH and metal ion condition. Bioinformatics confirm the conservation 
of ENDOV’s catalytic residue from E. coli to Homo sapiens, and it is thus surprising that no 
endonucleolytic activity for hENDOV has been discovered.  
 Regarding the biochemistry of human ENDOV, optimization of the DNA binding 
protocol and extension of the enzymatic assay should be explored to reveal possible 
endonucleolytic activity. In these experiments, possible protein partners and sequence specific 
DNA substrates should also be tested. Another way to identify protein partners or the pathway 
of ENDOV is by mapping of genetic interactions by double-mutant knockout experiment. 
Such analyses are most conveniently carried out using simpler model organisms like E. coli or 
yeast (S. pombe or S. cerevisiae) for prokaryotes and eukaryotes, respectively. 
 In summary, this thesis presents the first results of the characterization of the human 
ENDOV protein, which is highly conserved in all domains of life, yet probably with different 
roles in prokaryotic and eukaryotic cells. 
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Appendix I: NCBI Reference sequence (hENDOV) 
Homo sapiens endonuclease V transcript variant 1, mRNA 
NCBI Reference Sequence: NM_173627.3 
With exon 3 and short exon 9 + exon 10 
>gi|257467546|ref|NM_173627.3| Homo sapiens endonuclease V 
(ENDOV), transcript variant 1, mRNA 
GTGCGGAAGGGGTGCCCGGGACGAAGCCATGGCCCTGGAGGCGGCGGGAGGGCCGCCGGAGG
AAACGCTGTCACTGTGGAAACGGGAGCAAGCTCGGCTGAAGGCCCACGTCGTAGACCGGGAC
ACCGAGGCGTGGCAGCGAGACCCCGCCTTCTCGGGTCTGCAGAGGGTCGGGGGCGTTGACGT
GTCCTTCGTGAAAGGGGACAGTGTCCGCGCTTGTGCTTCCCTGGTGGTGCTCAGCTTCCCTG
AGCTCGAGGTGGTGTATGAGGAGAGCCGCATGGTCAGCCTCACAGCCCCCTACGTGTCGGGC
TTCCTGGCCTTCCGAGAGGTGCCCTTCTTGCTGGAGCTGGTGCAGCAGCTGCGGGAGAAGGA
GCCGGGCCTCATGCCCCAGGTCCTTCTTGTGGATGGAAACGGGGTACTCCACCACCGAGGCT
TTGGGGTGGCCTGCCACCTTGGCGTCCTTACAGACCTGCCGTGTGTTGGGGTGGCCAAGAAA
CTTCTGCAGGTGGATGGGCTGGAGAACAACGCCCTGCACAAGGAGAAGATCCGACTCCTGCA
GACTCGAGGAGACTCATTCCCTCTGCTGGGAGACTCTGGGACTGTCCTGGGAATGGCCCTGA
GGAGCCACGACCGCAGCACCAGGCCCCTCTACATCTCCGTGGGCCACAGGATGAGCCTGGAG
GCCGCTGTGCGCCTGACTTGCTGCTGCTGCAGGTTCCGGATCCCAGAGCCCGTGCGCCAGGC
TGACATCTGCTCCCGAGAGCACATCCGCAAGTCGCTGGGACTCCCCGGGCCACCCACACCGA
GGAGCCCGAAGGCGCAGAGGCCAGTGGCATGCCCCAAAGGAGACTCCGGAGAGTCCTCAGCA
CTTTGTTGAACGTGGTGGTGAGAGCACACGTCCTCGTCTCATTCCTGATCGAACGCGGTGGT
GAGAGCACACGTCCTCGTCTCGTTCCTGATCGAACGCGGTGGTGAGAGCA 
 
MALEAAGGPPEETLSLWKREQARLKAHVVDRDTEAWQRDPAFSG                     
LQRVGGVDVSFVKGDSVRACASLVVLSFPELEVVYEESRMVSLTAPYVSGFLAFREVP                    
FLLELVQQLREKEPGLMPQVLLVDGNGVLHHRGFGVACHLGVLTDLPCVGVAKKLLQV                     
DGLENNALHKEKIRLLQTRGDSFPLLGDSGTVLGMALRSHDRSTRPLYISVGHRMSLE                     
AAVRLTCCCCRFRIPEPVRQADICSREHIRKSLGLPGPPTPRSPKAQRPVACPKGDSG               
ESSALC 
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Homo sapiens endonuclease V transcript variant 2, mRNA 
NCBI Reference Sequence: NM_001164637.1 
Without exon 3 and short exon 9 + exon 10 
>gi|257467547|ref|NM_001164637.1| Homo sapiens endonuclease V 
(ENDOV), transcript variant 2, mRNA 
GTGCGGAAGGGGTGCCCGGGACGAAGCCATGGCCCTGGAGGCGGCGGGAGGGCCGCCGGAGG
AAACGCTGTCACTGTGGAAACGGGAGCAAGCTCGGCTGAAGGCCCACGTCGTAGACCGGGAC
ACCGAGGCGTGGCAGCGAGACCCCGCCTTCTCGGGTCTGCAGAGGGTCGGGGGCGTTGACGT
GTCCTTCGTGAAAGGGGACAGTGTCCGCGCTTGTGCTTCCCTGGTGGTGCTCAGCTTCCCTG
AGCTCGAGGTCCTTCTTGTGGATGGAAACGGGGTACTCCACCACCGAGGCTTTGGGGTGGCC
TGCCACCTTGGCGTCCTTACAGACCTGCCGTGTGTTGGGGTGGCCAAGAAACTTCTGCAGGT
GGATGGGCTGGAGAACAACGCCCTGCACAAGGAGAAGATCCGACTCCTGCAGACTCGAGGAG
ACTCATTCCCTCTGCTGGGAGACTCTGGGACTGTCCTGGGAATGGCCCTGAGGAGCCACGAC
CGCAGCACCAGGCCCCTCTACATCTCCGTGGGCCACAGGATGAGCCTGGAGGCCGCTGTGCG
CCTGACTTGCTGCTGCTGCAGGTTCCGGATCCCAGAGCCCGTGCGCCAGGCTGACATCTGCT
CCCGAGAGCACATCCGCAAGTCGCTGGGACTCCCCGGGCCACCCACACCGAGGAGCCCGAAG
GCGCAGAGGCCAGTGGCATGCCCCAAAGGAGACTCCGGAGAGTCCTCAGCACTTTGTTGAAC
GTGGTGGTGAGAGCACACGTCCTCGTCTCATTCCTGATCGAACGCGGTGGTGAGAGCACACG
TCCTCGTCTCGTTCCTGATCGAACGCGGTGGTGA 
 
MALEAAGGPPEETLSLWKREQARLKAHVVDRDTEAWQRDPAFSG                   
LQRVGGVDVSFVKGDSVRACASLVVLSFPELEVLLVDGNGVLHHRGFGVACHLGVLTD                     
LPCVGVAKKLLQVDGLENNALHKEKIRLLQTRGDSFPLLGDSGTVLGMALRSHDRSTR                     
PLYISVGHRMSLEAAVRLTCCCCRFRIPEPVRQADICSREHIRKSLGLPGPPTPRSPK 
AQRPVACPKGDSGESSALC 
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Homo sapiens endonuclease V, transcript variant 3, mRNA 
NCBI Reference Sequence: NM_001164638.1 
Without exon 3 and with full-length exon 9 
>gi|257467549|ref|NM_001164638.1| Homo sapiens endonuclease V 
(ENDOV), transcript variant 3, mRNA 
GTGCGGAAGGGGTGCCCGGGACGAAGCCATGGCCCTGGAGGCGGCGGGAGGGCCGCCGGAGG
AAACGCTGTCACTGTGGAAACGGGAGCAAGCTCGGCTGAAGGCCCACGTCGTAGACCGGGAC
ACCGAGGCGTGGCAGCGAGACCCCGCCTTCTCGGGTCTGCAGAGGGTCGGGGGCGTTGACGT
GTCCTTCGTGAAAGGGGACAGTGTCCGCGCTTGTGCTTCCCTGGTGGTGCTCAGCTTCCCTG
AGCTCGAGGTCCTTCTTGTGGATGGAAACGGGGTACTCCACCACCGAGGCTTTGGGGTGGCC
TGCCACCTTGGCGTCCTTACAGACCTGCCGTGTGTTGGGGTGGCCAAGAAACTTCTGCAGGT
GGATGGGCTGGAGAACAACGCCCTGCACAAGGAGAAGATCCGACTCCTGCAGACTCGAGGAG
ACTCATTCCCTCTGCTGGGAGACTCTGGGACTGTCCTGGGAATGGCCCTGAGGAGCCACGAC
CGCAGCACCAGGCCCCTCTACATCTCCGTGGGCCACAGGATGAGCCTGGAGGCCGCTGTGCG
CCTGACTTGCTGCTGCTGCAGGTTCCGGATCCCAGAGCCCGTGCGCCAGGCTGACATCTGCT
CCCGAGAGCACATCCGCAAGTCGCTGGGACTCCCCGGGCCACCCACACCGAGGAGCCCGAAG
GCGCAGAGGCCAGTGGCATGCCCCAAAGGAGACTCCGGAGAGTCCTCAGGTGAGGGCCAGCC
CCCACAGGACCACAGCCCAGGCCCCAGGACAGCCCCAAGGCCAGGCTCCCAGGAGCAGGCGG
GCAAGGACTGGCAGTAGGGTGGAACTGGGCACCATGAAGACAAGAAGGCCACCGGCCACCCC
GTTCTGGCCTCAGGACACTGACCACCCCTGGGGGTGGTCTAG 
 
MALEAAGGPPEETLSLWKREQARLKAHVVDRDTEAWQRDPAFSG                     
LQRVGGVDVSFVKGDSVRACASLVVLSFPELEVLLVDGNGVLHHRGFGVACHLGVLTD                     
LPCVGVAKKLLQVDGLENNALHKEKIRLLQTRGDSFPLLGDSGTVLGMALRSHDRSTR                     
PLYISVGHRMSLEAAVRLTCCCCRFRIPEPVRQADICSREHIRKSLGLPGPPTPRSPK 
AQRPVACPKGDSGESSGEGQPPQDHSPGPRTAPRPGSQEQAGKDW
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Appendix II: Raw data for MTT-assay 
Early transformed MEF cell treated with CPT 
Table A. Comparison between the different MEF WT cell lines (relative values). 
CPT  (µM) 0 0,1 0,5 1 2 3 5 n 
WT #2 100 79,0 69,1 63,7 51,6   2 
WT #3 100 56,9 36,7 30,1 25,2 2,3 3,1 5 
WT #5 100 58,7 35,0 30,8 25,8 41,0 38,5 5 
WT #6  100 66,7 50,6 44,9 45,5   3 
         
Average 100 65,3 47,8 42,4 37,0 21,6 20,8  
STDEV  10,0 15,8 15,7 13,5 27,3 25,0  
 
Table B. Comparison between the different MEF KO cell lines (relative values). 
CPT (µM) 0 0,1 0,5 1 2 3 5 n 
KO #2 100 69,9 53,6 45,0 37,7 35,3 27,1 5 
KO #3 100 45,2 25,6 18,5 14,9   3 
KO #4 100 68,8 50,8 41,1 34,0 33,0 29,0 5 
KO #5 100 47,4 18,5 10,7 7,8 9,4 8,8 5 
         
         
Average 100 57,8 37,1 28,8 23,6 25,9 21,6  
STDEV  13,3 17,7 16,8 14,5 14,4 11,2  
 
Table C. Comparison between MEF WT and KO (relative values). 
WT 0 0,1 0,5 1 2 3 5 
Average 100 65,3 47,8 42,4 37,0 21,6 20,8 
STDEV  10,0 15,8 15,7 13,5 28,6 31,7 
        
KO 0 0,1 0,5 1 2 3 5 
Average 100 57,8 37,1 28,8 23,6 25,9 21,6 
STDEV  13,3 17,7 16,8 14,5 14,4 11,2 
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Primary MEF cell treated with CPT 
 
Table D. Comparison between the different MEF WT cell lines (relative values). 
CPT (µM) 0 0,05 0,1 0,5 1 2 4 6 n 
WT #2 100 86,2 74,2 62,1 46,9 41,9 37,8  2 
WT #3 100 86,9 82,0 71,6 55,0  41,9 43,4 5 
WT #4 100 79,1 69,6 46,3 36,4 34,3 34,6  2 
WT #5 100 65,4 62,9 48,6 40,5  29,1 29,7 5 
WT #6  100 57,8 52,8 42,2 36,3  26,8 28,5 4 
          
Average 100 75,1 68,3 54,2 43,0 38,1 34,0 33,8  
STDEV  12,9 11,1 12,3 8,0 5,4 6,2 8,3  
 
Table E. Comparison between the different MEF KO cell lines (relative values). 
CPT (µM) 0 0,05 0,1 0,5 1 2 4 6 n 
KO #2 100 78,6 71,7 57,0 41,6 35,3 37,8  3 
KO #3 100 63,9 60,0 45,3 32,6  18,6 19,4 5 
KO #4 100 77,5 70,7 46,4 35,5 29,4 29,0  2 
KO #5 100 62,4 56,6 44,3 31,7  19,3 20,7 5 
KO #6 100 69,8 65,7 55,8 49,2  37,0 38,7 4 
          
Average 100 70,4 64,9 49,8 38,1 32,3 28,3 26,3  
STDEV  7,5 6,6 6,1 7,3 4,2 9,2 10,8  
 
Table F. Comparison between MEF WT and KO (relative values). 
WT 0 0,05 0,1 0,5 1 2 4 6 
Average 100 75,1 68,3 54,2 43,0 38,1 34,0 33,8 
STDEV  12,9 11,1 12,3 8,0 5,4 6,2 8,3 
         
KO 0 0,05 0,1 0,5 1 2 4 6 
Average 100 70,4 64,9 49,8 38,1 32,3 28,3 26,3 
STDEV  7,5 6,6 6,1 7,3 4,2 9,2 10,8 
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Primary MEF cell treated with MMS, MMC and gamma radiation  
 
Table G. Comparison between MEF WT and KO treated with MMS (µM) (relative values). 
WT 0 50 100 120 140 180 200 
Average 100 82,1 80,2 73,3 66,4 55,3 34,8 
STDEV  6,8 4,6 7,5 2,6 4,4 2,6 
        
KO 0 50 100 120 140 180 200 
Average 100 83,4 77,1 75,0 67,0 55,6 46,3 
STDEV  4,0 7,3 9,5 8,1 8,3 1,9 
 
Table H. Comparison between MEF WT and KO treated with MMC (µM) (relative values). 
WT 0 0,1 0,5 1 5 10 20 
Average 100 89,3 84,4 80,8 70,0 51,6 37,5 
STDEV  3,5 3,4 6,4 7,2 2,2 3,3 
        
KO 0 0,1 0,5 1 5 10 20 
Average 100 85,3 81,2 78,9 66,5 46,6 34,8 
STDEV  4,1 5,8 5,3 3,8 2,7 0,7 
 
Table I. Comparison between MEF WT and KO irradiated with gamma (Gy) (relative values). 
WT 0 20 40 60 
Average 100 93,0 82,4 78,5 
STDEV  6,1 2,2 0,2 
     
KO 0 20 40 60 
Average 100 89,2 84,1 73,8 
STDEV  5,4 1,8 1,1 
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Appendix III: Multiple sequence alignments 
 
Mulltiple sequence alignment of endonuclease V proteins from different organisms 
Key catalytic residues are indicated by black arrows and the residues forming the binding 
pocket are indicated by blue arrows. 
 
Figure A. Multiple sequence alignment of Endonuclease V proteins from different organisms. Mouse: Mus 
musculus, dog: Canis familiaris, GuinPig: Cavia porcellus, Swine: Sus scrofa, Human: Homo sapiens, 
NP_229661.1-Tmaritima: Thermotoga maritima, NFI_ECOLI: Escherichia coli, NP_822860.1Savermitilis: 
Streptomyces avermitilis, and CAB0750.1Bsubtilis: Bacillus subtilis. (J.K. Lærhahl, unpublished data). 
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Multiple sequence alignment of endonuclease V proteins from different mammals 
 
Figure B. Multiple sequence alignment of Endonuclease V proteins from the mammalian organisms mouse (Mus 
musculus), rat (Rattus norvegicus), dog (Canis familiaris), gorilla (Gorilla gorilla), guinea pig (Cavia porcellus), 
orangutan (Pongo pygmaeus), pig (Sus scrofa), tenrec (Ecinops telfairi) and human (Homo sapiens)  
(J.K. Lærhahl, unpublished data). 
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Appendix IV: Vector maps 
Vector map of pEGFP-N1 from Clontech 
 
Vector map pEGFP-C1 from Clontech 
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Units of measurements 
 
°C Degrees Celcius mg Milligram (10
-3
 g) 
g Gram ml Millilitre (10
-3
 L) 
g G force mM Millimolar (10-
3
 M) 
kb Kilobases (10
3
 b) nm Nanometer (10
-9
 m)  
kDa Kilo Dalton (10
3
 Da) ng Nanogram (10
-9
 g) 
L Litre µg Microgram (10
-6
 g) 
M Molar µl Microlitre (10
-6
 L) 
  V Volt 
 
